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Summary 
Survivin, the smallest and functionally unique member of the inhibitor of apoptosis protein 
(IAP) family, is frequently overexpressed in malignant cells and has been acknowledged as a 
predictive molecular marker for metastases and cancer patient survival following radiation 
therapy. The role of this protein in cellular radiation response, however, far exceeds a simple 
inhibition of apoptotic cell death involving non-caspase dependent mechanisms such as 
regulation of cell cycle and DNA damage repair. To investigate in more detail the role of 
Survivin in cellular radiation response and tumour cell motility, the present study aimed to 
establish and stably express several Survivin enhanced green fluorescent protein (EGFP)-
tagged deletion or phosphorylation mutant constructs in SW480 colorectal cancer cells. To 
this end, Survivin wild-type (Surv. wt) and recombinant proteins lacking the binding sites for 
X-linked IAP (XIAP), Microtubules and heat shock protein 90 (Hsp90) (Survivin 
XIAP/MicTub/Hsp90) or the baculovirus IAP repeat (BIR) domain (Survivin BIR) as well 
as phosphorylation mutants for the sites S20, T34 and T117 (Survivin 
S20A/S20D/T34A/T34D/T117A/T117D) were expressed in a pEGFP-N1 vector system. 
Subsequently, these mutant clones were subjected to more physiologic three-dimensional 
(3D) colony forming assays, immunofluorescence staining of DNA double strand break 
markers H2AX and 53BP1, analysis of cell cycle distribution, induction of apoptosis, 
caspase 3/7 activity and transmigration assays following irradiation with doses ranging from 
1 to 6 Gy. While knockdown of endogenous Survivin by RNA interference (siRNA) resulted in 
a significantly decreased 3D radiation survival in line with elevated numbers of residual 
H2AX/53BP1 foci in pEGFP-N1 vector control, Survivin XIAP, BIR and T34A clones, both 
radiation clonogenic survival and the capacity to regulate DNA repair was rescued in clones 
stably overexpressing Survivin wt, MicTub, Hsp90 and Survivin T34D mutant cells. 
Moreover, deletion of the BIR domain, XIAP, Microtubules and Hsp90 binding sites resulted 
in a G2/M cell cycle arrest, an elevated percentage of apoptotic SubG1 cells, an increased 
caspase 3/7 activity and significantly hampered transmigration activity of SW480 cells 
following depletion of endogenous Survivin. On a molecular level, constructs derived from 
Survivin XIAP and T34A phospho-mutant overexpressing clones did not co-
immunoprecipitate with the DNA repair protein DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs), whereas Survivin wt and T34D constructs co-precipitated with the 
protein. These data confirm Survivin to act as a radiation resistance factor modulating 
cellular radiation response by multiple mechanisms including DNA DSB repair, induction of 
cell cycle arrest and apoptosis. It is for the first time indicated that Survivin’s XIAP binding 
and T34 phosphorylation sites, but not its Microtubules and Hsp90 binding sites, are 
essential for radiation clonogenic survival and modulation of DNA damage repair, at least in 
 xi 
part by disturbing protein interaction with DNA-PKcs. On the contrary, XIAP, Hsp90 and 
Microtubules binding sites as well as the BIR domain were shown to be essential for proper 
cell cycle regulation, apoptosis inhibition and transmigration capacity of SW480 colorectal 
adenocarcinomas. 
 
Zusammenfassung (summary in German) 
Survivin, das kleinste und funktionell einzigartige Mitglied der Inhibitor of Apoptosis Protein 
(IAP) Familie ist in der Mehrzahl maligner Zellen überexpremiert und stellt einen 
wesentlichen prädiktiven molekularen Marker für eine Metastasierung und das Überleben 
von Patienten nach Strahlentherapie dar. In diesem Zusammenhang wurde zudem gezeigt, 
dass die Rolle von Survivin in der zellulären Strahlenantwort weit über eine alleinige 
Hemmung der apoptotischen Reaktionskaskaden hinausgeht, sondern vielmehr auch 
Caspase-unabhängige Mechanismen wie eine Regulation des Zellzyklus und der Reparatur 
von DNA-Schäden beinhaltet. Um die Rolle von Survivin in der zellulären Strahlenantwort 
und Tumorzellmotilität detaillierter zu untersuchen, war es Ziel der vorliegenden Arbeit, eine 
Reihe von grün fluoreszierendes Protein (GFP) markierten Survivin Deletions- und 
Phosphorylierungsmutanten zu generieren und stabil exprimierende  Klone kolorektaler 
SW480 Karzinomzellen herzustellen. Dazu wurden wildtyp-Survivin und rekombinante 
Proteine mit fehlenden Bindungsstellen für X-linked IAP (XIAP), Mikrotubuli, 
Hitzeschockprotein 90 (Surv-XIAP/MicTub/Hsp90), die Baculovirus IAP Repeat (BIR) 
Domäne (Surv-BIR), sowie Mutanten der Phosphorylierungsstellen S20, T34 und T117 
(Survivin S20A/ S20D/T34A/T34D/T117A/ T117D) in einem pEGFP-N1 Vektor System zur 
Expression gebracht. Anschließend wurden die Zellen unter physiologischen Bedingungen in 
drei-dimensionalen (3D) Koloniebildungstests eingesetzt, die Expression der DNA-
Doppelstrangbruchmarker  H2AX und 53BP1 mittels Immunfluoreszenz quantifiziert und die 
Zellzyklusverteilung, Induktion von Apoptose und die Caspase 3/7 Aktivität bzw. die 
Transmigrationsfähigkeit nach Bestrahlung mit Dosen von 1 bis 6 Gy untersucht. Während 
die Hemmung von endogenem Survivin durch RNA-Interferenz (siRNA) zu einer 
signifikanten Minderung des 3D klonogenen Überlebens und einer erhöhten Anzahl 
residueller H2AX/53BP1 Foci in pEGFP-N1 Kontrollvektor, Surv. XIAP, Surv. BIR und 
Surv. T34A transfizierten Zellen führte, konnte das radiogene Zellüberleben und die DNA-
Reparaturkapazität in stabil Surv. wt, Surv. MicTub, Surv. Hsp90 und Surv. T34D 
überexprimierenden Zellklonen rekonstituiert werden. Darüber hinaus führte die Deletion der 
BIR Domäne, der Mikrotubuli und der Hsp90 Bindungsstelle zur Induktion eines G2/M 
Zellzyklus-Arrestes, einem erhöhten Anteil apoptotischer SubG1 Zellen, einer gesteigerten 
Caspase 3/7 Aktivität und einer signifikanten Hemmung der Transmigration von SW480 
Zellen nach Attenuation des endogenen Survivins. Auf molekularer Ebene gelang bei 
Konstrukten aus Surv. XIAP and T34A Phospho-mutanten überexpremierenden Zellen 
keine Ko-Immunpräzipitation mit dem DNA Reparaturprotein DNA Proteinkinase (DNA-
PKcs), während dies bei wt-Survivin Klonen sowie bei der T34D phospho-mimetischen 
Mutante möglich war. Zusammengefaßt bestätigen diese Daten die Aktivität von Survivin als 
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Radioresistenzfaktor, der die zelluläre Bestrahlungsantwort durch multiple Mechanismen, 
einschließlich der DNA- Doppelstrangbruch-Reparatur und der Induktion eines Zellzyklus 
Arrestes und von Apoptose zu modulieren vermag. Darüber hinaus konnte hier erstmals 
gezeigt werden, dass die XIAP Bindungs- und T34 Phosphorylierungs-, nicht jedoch die 
Microtubuli und Hsp90 Bindungsstellen essentiell für das klonogene Zellüberleben nach 
Bestrahlung und die Modulation der DNA Schadensreparatur sind. Dies beruht, zumindest 
teilweise, auf der Beeinträchtigung der Interaktion mit dem Protein DNA-PKcs. Im Gegensatz 
dazu sind für die Regulation des Zellzklus, die Inhibition der Apoptose und das 
Migrationsverhalten der kolorektalen Adenokarzinomlinie SW480 sowohl die XIAP-, die 
Hsp90- und die Mikrotubuli-Bindungsstellen wie auch die BIR-Domäne wesentlich. 
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1. Introduction 
1.1 Colorectal cancer 
Colorectal cancer (CRC), the second most common cancer in women and third in men, 
accounts for 1,233,700 cancer incidents annually worldwide, 608,700 cases of which 
eventually lead to death [1]. More than 95% of CRC cases are adenocarcinomas while 50% 
of the patients are diagnosed with distant metastasis or local recurrence with a median 
survival time of 4 to 22 months [2]. Although there are some environmental and lifestyle risk 
factors it is nowadays generally accepted that colorectal cancer is caused by changes in 
various molecular pathogenic pathways, such as CpG island methylator phenotype (CIMP), 
chromosomal instability (CIN) or microsatellite instability (MSI) [3].  
The CIN pathway is the one via which approximately 85% of CRCs are developed [4] mainly 
due to an accumulation of numerical or structural chromosomal anomalies [5]. In this 
pathway the earliest detectable lesion is a microscopic mucosal dysplasia named aberrant 
crypt focus (ACF) [6] which is followed by the development of a polyp [3, 7]. Typical 
aberrations during the CIN pathway include V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homologue (KRAS) oncogene mutation, deletion of 17p chromosome (which entails the 
tumour suppressor gene TP53) and loss of 18q chromosome [3, 4]. However, there are 
many alternative genetic and epigenetic changes that have recently been described [8] and 
will eventually be considered as complementary events to the aforementioned genetic 
mutations [3].   
A deficiency in the function of the tumour suppressor TP53 gene, typically via allelic loss of 
17p [3], is known to characterize 50-75% of CRCs [9]. The TP53 protein is responsible for 
the slowdown of cell cycle in order for the DNA damage to be repaired [3] as well as for the 
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induction of pro-apoptotic genes in case of an accumulation of unrepaired genetic damage 
[10]. 
Around 60% of CRCs demonstrate an allelic loss of 18p21.1, a site entailing SMAD2 and 
SMAD4 [11], both of them being involved in the transforming growth factor- (TGF-) 
signaling pathway which is essential for apoptosis and growth regulation [3].  
In the case of MSI, microsatellites typically consist of 1-5 nucleotide tandem repeats found 
throughout the whole genome and MSI corresponds to an inconsistency in the amount of 
those microsatellites between normal and tumour cells [3, 12]. MSI phenotype can arise from 
mutations interfering with the mismatch repair (MMR) machinery, a condition present in 
approximately 15% of colorectal cancers [13-15]. It is now understood that the colorectal 
cancer genome entails probably thousands molecular aberrations certain subsets of which 
take part in carcinogenesis [12].  
Approximately 15% of all sporadic colorectal cancers are originated by the CIMP pathway 
[16, 17]. KRAS, v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) and MSI 
mutations often occur in the case of CIMP cancers which are also related to older age, 
genetic predisposition or the female gender [18]. In general, genetic and epigenetic 
aberrations can take place in numerous combination patterns with some genes exclusively 
modified by epigenetic inactivation and others being both genetically and epigenetically 
inactivated [18].  
Coloretal cancer therapeutic approaches vary depending on numerous factors such as 
tumour localization and stage, involvement of tumour positive lymph nodes etc., with the 
majority of such therapies to involve surgical resection followed by adjuvant chemotherapy in 
case of colon carcinoma. By contrast, neoadjuvant (preoperative) combined radiation and 
chemotherapy (comprised of 5-Fluorouracil along with additional agents such as oxaliplatin, 
or irinotecan) became standard therapy for patients with locally advanced rectal cancer [19].  
Introduction 3  
 
1.2 Inhibitor of apoptosis proteins (IAPs) 
In 1993 a baculovirus gene that inhibits apoptosis in virally infected Spodoptera frugiperda 
insect cells was discovered [20] and since then several cellular homologues have been 
detected in yeast, nematodes, flies and higher vertebrates. It is generally known that IAPs 
are important for cell division, morphogenesis, nuclear factor kappa B (NF-B) activation, 
heavy metal homeostasis and Mitogen-activated protein (MAP) kinase signaling [21]. IAPs 
are characterized by the presence of a variable number of Baculoviral IAP Repeat (BIR) 
motifs comprised of approximately 70 amino acids coordinating a zinc ion through cysteine 
and histidine residues [21]. Apoptosis being a controlled cell suicide process which plays a 
pivotal role in homeostasis and development of the organism, when deregulated can lead to 
various pathogenic conditions including cancers, neurological disorders and autoimmunity 
[21]. The fact that many neoplasms are found to express a high level of IAPs along with a 
genetic translocation regarding the gene encoding cellular IAP2 (c-IAP2) detected in a 
subset of B cell lymphomas led to the notion that IAPs contribute to apoptotic cell death 
resistance that characterizes numerous cancers [21]. It was originally thought that those 
proteins were physical caspase inhibitors representing a cytoprotective factor downstream of 
death receptors [22, 23]. It is now obvious that IAPs not only regulate caspases via 
mechanisms distinctive for each member of the family [24] but also participate in several 
aspects of cellular homeostasis [21, 25].  
The function of IAPs depends not only on their distinct domains but also on posttranslational 
modifications and changes at the level of expression [21]. In particular, protein-protein 
interactions, intracellular localization and IAP stability are influenced by phosphorylation of 
some IAPs [26-28] while interactions among IAP molecules can have an effect on their 
expression levels [29-32].  
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Figure 1: Symbolic representation of structural domains of IAPs. Domains such as the BIR (Baculovirus IAP 
repeat) and RING (really interesting new gene) shown here characterize all members of the IAP family (except 
Survivin). DIAP1: Drosophila IAP 1; UBA: binding site for polyubiquitinated proteins; CARD: caspase-associated 
recruitment domain; c-IAPs: cellular IAPs; XIAP: X-linked inhibitor of apoptosis protein. (Figure adapted from [22])  
 
A structural characteristic common to all IAPs is the BIR domain which can be found either in 
a single copy or two to three repeats in the N-terminus along with other functional domains 
like a really interesting new gene (RING) or caspase-associated recruitment domain (CARD) 
in the proximity of C-terminal region of the proteins [21] (Figure 1). BIR domains fold as 
three-stranded -sheets surrounded by four -helices and their signature sequence is 
CX2CX16HX6C, where C = cysteine, H = histidine and X stands for any amino acid [33-36]. C-
IAP1 (cellular IAP1), c-IAP2 (cellular IAP2) and XIAP (X-linked IAP) contain three BIRs and 
one RING domain, functioning as an E3 ubiquitin ligase (a ubiquitin-associated domain 
involved in binding to ubiquitinated proteins) and a CARD in c-IAP1 and c-IAP2 whose 
function is not fully understood [22]. In spite of the resemblance all BIR domains bear, 
different BIRs identify different intermediates and participate in distinct signaling pathways 
[21].   
In principal, BIRs are involved in protein-protein interactions as well as protein recognition 
[21], as a peptide-binding groove (in the case of XIAP, c-IAP1 and c-IAP2) comprises a  
hydrophobic recognition site for IAP-binding motif (IBM) entailing proteins [22]. Certain 
XIAP
c-IAPs
DIAP1
Survivin
Livin
BIR1
BIR1
BIR1
BIR2
BIR2
BIR2
BIR
BIR
-helix
BIR3
BIR3
UBA
UBA CARD
RING
RING
RING
RING
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apoptosis inducers such as second mitochondrial-derived activator of caspase (Smac) also 
known as direct IAP-binding protein with low isoelectric point (DIABLO) along with initiator 
capsase 9 and effector caspase 7 contain an IBM i.e. a tetrapeptide region with an invariant 
N-terminal alanine residue and other conserved residues [37, 38]. Short peptides that contain 
SMAC IBM can prevent BIR3 from binding to caspase 9 [39]. The binding of XIAP and Smac 
is greatly increased due to the tandem presence of BIR2 and BIR3 in XIAP, as Smac forms a 
stable complex with XIAP in a ratio of 2:1 via concurrent interaction with both BIR2 and -3 
[21]. Not every BIR domain contains an IBM recognition site [40] as for example, the XIAP 
BIR1 does not bind caspases or IBM containing proteins, but identifies molecules involved in 
NF-B activation instead [41, 42].  
In general, the interaction between caspases and IAPs occurs via IBM-dependent 
complexes, resulting in the abolishment of enzymatic activity of caspases [22, 38]. While this 
was originally thought to be the sole role of IAPs [43], it is now commonly accepted that only 
XIAP (from the mammalian IAPs) actually inhibits caspases in vivo [25]. XIAP interacts with 
caspases 3, 7 and 9, obliterating their cell killing ability [22]. The XIAP linker region upstream 
of BIR2 interacts with the catalytic cleft of caspases 3 and 7, inhibiting substrate accessibility 
thus eliminating their activity [44-46]. Caspase 9 is inhibited via XIAP BIR3 as the latter 
interferes with the homodimerization domain of the enzyme, abolishing the conformational 
change required for activity [47].  XIAP participates also in cell-death regulation through its 
RING domain [21] the mechanism of which has not yet been clarified, although recent 
studies revealed a cytoprotective role for the RING domain when mice expressing a BIR-only 
type of XIAP showed an increased caspase activity and cell death in vivo [48].  
Members of the IAP family bind to each other via their BIR domains [21]. For instance, the 
BIR1 and -3 from XIAP are responsible for binding with the single BIR of Survivin in order to 
form a complex of increased stability against proteasomal degradation and synergistically 
inhibit apoptosis [31]. Survivin BIR also binds Aurora B, a serine/threonine kinase involved in 
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the regulation of cell division, as well as Borealin and inner centromere protein (INCENP) 
thus forming the chromosomal passenger complex (CPC) [49].  
The RING domain is characterized by the presence of one or two histidines and six to seven 
cysteines comprising a cross-brace structure that coordinates two zinc ions [50]. These 
domains mediate ubiquitin protein ligase (E3) activity as the transfer of ubiquitin to target 
proteins is facilitated by a ubiquitin activating enzyme (E1) and a ubiquitin conjugating 
enzyme (E2) [51]. All IAPs that entail RING domains demonstrate E3 activity involving 
apoptotic and signaling molecules as well as themselves in a homo- or heterotypic fashion 
[21].  
In cells exposed to pro-apoptotic stimuli, XIAP, c-IAP1 and c-IAP2 undergo autoubiquitination 
in a RING dependent manner, a process found abrogated in a RING-mutant XIAP lacking E3 
activity [52, 53]. Those pro-apoptotic stimuli are able to cause IAP autoubiquitination due to 
IBM-containing IAP antagonists that are released [54].  
Apart from caspase inhibition, IAPs were also found to modulate NF-B, a transcription factor 
pivotal for inflammation, cell survival, migration, invasion and immunity [55-57]. 
Consequently, IAP-mediated NF-B activation can result in tumour progression and 
metastasis [58]. 
IAPs are found to be overexpressed in many tumour entities as inhibition of apoptosis plays 
a major role in carcinogenesis by enabling cell survival in unfavourable conditions typically 
hostile to non-cancerous cells. For instance, the fact that Survivin is overexpressed in breast, 
colorectal, esophageal/gastric carcinoma, lymphoma and neuroblastoma as well as the poor 
prognosis with which this overexpression is associated with, led to the hypothesis that IAP 
up-regulation might comprise an oncogenic event [59, 60]. Besides Survivin (which will be 
further analyzed in section 1.4), c-IAP1 and c-IAP2 also play a role in mammalian cancers 
with high levels of c-IAP1 to promote carcinogenesis [61, 62]  and c-IAP2 being correlated 
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with a type of neoplasia called MALT (mucosa-associated lymphoid tissue) lymphomas [63]. 
Another way for tumour cells to evade apoptosis is to down-regulate molecules that cause 
suppression of XIAP’s caspase-inhibitory activity, such as XIAP-associating factor 1 (XAF1) 
whose levels have been reported to be decreased in some cancer cell lines [64, 65].  
As IAPs are implicated in tumourigenic events, their expression has been targeted via RNA 
interference methods and alternatively, compounds mimicking naturally occurring IAP 
antagonists have been developed in order to neutralize IAP function [66]. For instance, 
Survivin suppression has been shown to sensitize tumour cells to both chemo- [59, 67, 68] 
and radiation therapy. 
 
1.3 DNA damage repair 
Higher eukaryotic cells have in the course of evolution acquired complex molecular 
mechanisms to preserve chromosomal integrity in their genomes amid background radiation, 
byproducts of cellular metabolism and environmental mutagens [69]. Maintaining genomic 
stability is essential for prevention of chromosomal rearrangements that can result in cancer 
via altered gene expression [70, 71]. There is a wide range of different types of DNA damage 
that can arise within the cell, with the DNA double-strand breaks (DSBs) being of great 
importance as they can cause cell death or cancer if improperly repaired [69, 72]. Ionizing 
radiation, reactive oxygen species as well as certain types of anti-cancer drugs are able to 
give rise to this type of lesion which is met mainly by two different repair mechanisms that 
mammalian cells have evolved: homologous recombination (HR) and non-homologous end 
joining (NHEJ) [69]. An intact sister chromatid is required for HR to take place which is, 
therefore, restricted to the S and G2 cell cycle phases. On the other hand, in the case of 
NHEJ the two broken DNA ends are re-joined without the need of a sister chromatid, a fact 
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that renders NHEJ functional in all cell cycle phases and thus the major DSBs repair 
mechanism in mammalian cells.  
A protein kinase central to the damage response signal transduction regarding DSBs is the 
ataxia telangiectasia mutated (ATM) [73] which is recruited to DSB lesions via the Mre11-
Rad50-Nbs1 (MRN) complex [74]. Following ATM activation (after being auto-
phosphorylated) [75] another part of this signalling cascade is the phosphorylation of a 
histone H2A variant, thus, generating H2AX which in turn facilitates the recruitment of other 
key proteins [such as p53-binding protein 1 (53BP1), mediator of DNA damage checkpoint 
protein 1 (MDC1), breast cancer 1 early onset (BRCA1), etc.] at DSB sites [76, 77].  
NHEJ is the predominant pathway through which irradiation-induced DSBs are repaired [78-
81]. This process is known to commence with the binding of Ku70 and Ku80 proteins, to 
double-stranded DNA ends in a manner that allows Ku to translocate along the DNA [82-84] 
and eventually recruit a large catalytic subunit of the DNA-dependent protein kinase complex 
(DNA-PKcs) [85, 86]. DNA-PKcs seems to be responsible for the regulation of the DNA ends 
processing to generate the 3’-OH and 5’-P ends required for ligation [87, 88]. The assembly 
of Ku and DNA-PKcs on DNA ends is followed by recruitment of a complex termed DNA 
ligase IV-X-ray repair cross-complementing protein 4 (XRCC4) that facilitates the re-joining 
step [89-92].       
 
1.4 Survivin 
Survivin, a 16.5 kDa protein of 142 amino acid residues encoded by the BIRC5 gene, is a 
member of the IAP family firstly described by Ambrosini et al. in 1997 [93]. Survivin is the 
smallest member of this protein family consisting of a single BIR domain [36] and an 
extended C-terminal -helix [93]. When in solution, Survivin forms a stable homodimer [36] 
while clear evidence rendering such an architecture necessary for function is still missing. On 
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the other hand, it is the monomeric protein that is involved in nuclear-cytoplasmic shuttling 
[94] and key protein recognition such as binding to the chromosomal passenger protein 
Borealin [49, 95].  
Survivin has been shown to function in a cytoprotective manner when in cytoplasm due to its 
anti-apoptotic activities [96] while when located in the nucleus it participates in cell division 
[97] and DNA repair regulation [98, 99]. It is expressed in a cell-cycle regulated manner with 
a peak at mitosis [97] showing a 40-fold up-regulation in G2/M phase when found to be 
localized in the mitotic apparatus [100]. Thus, Survivin is acknowledged to be an 
indispensable member of the chromosomal passenger complex [101, 102].  
Homozygous deletion of Survivin gene resulted in early embryonic death [103], while mitotic 
defects, cell death and tissue involution followed after conditional deletion of Survivin in adult 
tissues [104, 105]. Such a scenario has been repeatedly confirmed by studies conducted on 
Survivin orthologues in other model systems like C. elegans [106, 107] and yeast [108], 
demonstrating pivotal roles of this protein in mitosis regarding chromosomal segregation and 
cytokinesis. Survivin physically interacting with other members of the chromosomal 
passenger complex such as Borealin, Aurora B and INCENP [49], regulates chromosomal 
alignment, cytokinesis as well as chromatin-associated spindle assembly [102], whereas 
another pool of this protein stabilizes the mitotic spindle [109]. In order to do this, Survivin 
binds to polymerized microtubules through its C-terminal -helices [22] suppressing 
microtubule dynamics [110]. Those different pools of Survivin manage to work together 
probably due to post-translational modifications such as monoubiquitination by Lysine 48 
(L48) and L63, an event necessary for mitotic trafficking [111].  
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Figure 2: Schematic diagram of Survivin role in radiation response. When in the cytoplasm Survivin interacts 
with other members of the IAP family (such as XIAP) to inhibit apoptosis while when found in the nucleus it 
participates in cell division (being a member of the CPC) as well as it regulates DNA repair (interacting with DNA-
PKcs and other members of the DNA repair machinery). XIAP: X-linked IAP; CPC: Chromosomal passenger 
complex; DNA-PKcs: DNA-dependent protein kinase catalytic subunit; Smac: Second mitochondria-derived 
activator of caspases; (Figure adapted from [112]) 
 
Survivin being a multifunctional protein, interacts with a variety of protein partners in order to 
co-ordinate its different activities including apoptosis inhibition (via interaction with other 
IAPs), cell division (being a member of the CPC) and regulation of DNA DSBs repair 
(interacting with DNA-PKcs, Ku-70, 53BP1, etc.) (Figure 2) [98, 99, 112].  
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Figure 3: Symbolic illustration of Survivin protein structure. Functional domains, binding sites as well as 
phosphorylation sites of Survivin are shown here. XIAP: X-linked inhibitor of apoptosis protein; Smac: Second 
mitochondria-derived activator of caspase; INCENP: Inner centromere protein; Hsp90: Heat shock protein 90; 
NES: Nuclear export signal; PKA: Protein kinase A; Plk1: Polo-like kinase 1; CDK1: Cyclin-dependent kinase 1; 
S20: Serine 20; T34: Threonine 34; T117: Threonine 117. (Figure adapted from [112])  
 
Survivin entails various phosphorylation sites such as Serine 20 (S20), Threonine 34 (T34) 
and Threonine 117 (T117) [113-116] via which both protein stability and trafficking among the 
subcellular compartments are achieved [112]. There are also several molecules that interact 
with this protein including tubulin, heat shock protein 90 (Hsp90) [117], Hsp60 [118], aryl 
hydrocarbon receptor-interacting protein (AIP) [119] and other members of the IAP family like 
XIAP [58] (Figure 3). 
Except for XIAP, all other IAPs including Survivin do not show a direct binding to caspases 
[21]. In the case of Survivin, it is believed that apoptosis is inhibited only after its complex-
formation with XIAP [31] where Survivin BIR residues 15-38 [114] interact with BIR1 and 
BIR3 of XIAP [31]. Besides caspase inhibition, the Survivin-XIAP complex promotes XIAP 
stability (as well as Survivin stability) against ubiquitin-dependent degradation and it also 
leads to tumour growth in vivo [114] being involved in XIAP-mediated NF-B activation [58]. 
The latter event gives rise to NF-B-dependent transcription of fibronectin (an extracellular 
matrix protein) [58] which in turn engages 1 integrins at the cell surface activating cell 
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motility kinases, proto-oncogene c-Sarcoma (Src) and focal adhesion kinase (FAK) resulting 
in enhanced tumour cell migration, invasion and metastatic dissemination in vivo [58]. In 
order to regulate other functions (besides apoptosis inhibition) such as cytokinesis or mitotic 
spindle checkpoint, Survivin co-operates with other IAPs like BRUCE and c-IAP1 [28, 31, 
120].  
A plethora of pre-clinical studies on various cancer cell lines have shown that down-
regulation or antagonization of Survivin led to inhibition of tumour cell proliferation along with 
increased apoptosis as well as greater sensitivity to TNF-related apoptosis-inducing ligand 
(TRAIL), tumour necrosis factor- (TNF- ) and chemotherapeutic drugs in both cell culture 
and xenograft models [121, 122]. It is further known that Survivin renders a radiation 
resistance factor [123-125] the attenuation of which exerts a radiosensitization effect on 
tumour cells. For instance, Survivin down-regulation combined with ionizing radiation was 
followed by a diminished clonogenic survival in vitro (regarding colorectal carcinoma, 
glioblastoma, hepatocellular carcinoma and NSCLC cells) as well as tumour growth 
retardation in xenograft models [112]. The mechanisms behind such observations are indeed 
complex, by far exceeding a mere irradiation-induced apoptotic cell death [112]. In particular, 
inability to repair DNA damage is one of the caspase-independent mechanisms via which 
Survivin down-regulation can decrease tumour cell survival after irradiation, firstly described 
by Chakravarti et al. [124].  
Following this, Survivin-specific siRNA, anti-sense oligonucleuotide (ASO) or a small 
molecule inhibitor of Survivin expression called YM155, used in colorectal and non-small-cell 
lung carcinoma (NSCLC) cells showed a hampered DNA damage repair [126-128]. 
Additionally, Survivin was observed to accumulate in the nucleus after radiation exposure as 
well as directly interact with DNA DSB repair proteins such as DNA-PKcs, Ku70, MDC1, 
H2AX and 53BP1 in colorectal cancer cells and glioblastoma cells [98, 99]. Apart from a 
diminished radiation clonogenic survival following Survivin attenuation, both DNA-PKcs 
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kinase activity and the level of S2056 autophosphorylation of DNA-PKcs were significantly 
decreased [98, 99].  
In general, interference with IAP function or expression can seriously affect cellular 
homeostasis leading to human diseases, most importantly cancer. In neuroblastoma for 
instance, the Survivin locus on 17q25 has often been seen amplified [129] and in genome-
wide studies it was found to be the fourth top ‘transcriptome’ in malignancies of colon, lung, 
breast, brain and melanoma while being low or undetectable in the corresponding normal 
tissues [130]. However, this ‘cancer-specific’ overexpression of Survivin has not yet been 
fathomed. Survivin gene expression is up-regulated probably through various oncogenic 
pathways while other mechanisms are responsible for the silencing of Survivin gene via 
several tumour suppressor networks [131]. In normal tissues for example, Survivin levels can 
be maintained low thanks to activated tumour suppressor mechanisms [132], whereas the 
oncogene activation that takes place in transformed cells and is associated with loss of 
tumour suppression may be responsible for induction of Survivin gene expression in vivo 
[131].  
Some of the oncogenic pathways potentially responsible for the up-regulation of Survivin 
gene expression are the v-Ha-ras Harvey rat sarcoma viral oncogene homologue (c-Ha-Ras) 
[133], v-myc myelocytomatosis viral oncogene homologue (avian) (c-Myc) [134], wingless-
related integration site (WNT)/-catenin/transcription factor 4 (TCF4) [135], neurogenic locus 
notch homologue (Notch) [136] as well as transcription factors such as signal transduction 
and activator of transcription 3 (STAT 3) [137], E2F activators [138], NF-B [139] and 
hypoxia inducible factor 1 (HIF-1) [140].  
On the other hand, for the transcriptional repression of Survivin non-mutated tumour 
suppressor TP53, wild type adenomatous polyposis coli gene (APC) [141] and phosphatase 
and tensin homologue deleted from chromosome ten (PTEN) [142] are among the 
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candidates. 82% of rectal and 60% of colonic cancers are characterized by APC mutation 
[143] which appears to trigger colorectal carcinogenesis as this mutation results in up-
regulation of Survivin transcription via activation of -catenin/TCF-4 signaling [144]. The 
mechanisms however, through which Survivin transcription is eventually repressed or up-
regulated are not yet clear although it is assumed that they include direct binding to the 
Survivin promoter or modification of chromatin structure accessibility within the promoter 
region in the case of TP53 [145, 146] or attachment of forkhead box O1 (FOXO1) and 
FOXO3a transcription factors [142] (or APC protein in the case of PTEN [147]) onto the 
Survivin promoter. Another factor that is known to bind the Survivin promoter repressing 
transcription via epigenetic chromatin modifications, is the histone deacetylase silent mating 
type information regulation 2 homologue 1 (SIRT1) which is de novo transcribed via BRCA1 
[148, 149].         
In addition, non-transcriptional mechanisms may also interfere with Survivin expression in 
tumours, such as stabilization of Survivin mRNA in an mammalian target of rapamycin 
(mTOR)-mediated pathway described in prostate cancer [150]. 
According to numerous retrospective analyses of series of patients and genome-wide 
microarray studies, Survivin comprises a therapy resistance factor contributing to overall 
dismal disease outcome [59]. In particular, deregulated Survivin has an impact on mitotic 
transitions amongst tumour cells thus enabling viability of aneuploid cells [151], overcoming 
cell-cycle checkpoints [152], conferring resistance to microtubule-targeting molecules [153], 
as well as synergistically interacting with oncogenes such as Myc [154].  
At the moment, several phase I and II clinical trials targeting Survivin are either in progress or 
already completed, with a focus on the application of a second generation 2’-O-methoxy-
methyl modified ASO (LY2181308 or Gataparsen, Eli Lilly and Company, Indianapolis, USA), 
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the transcriptional inhibitor YM155 (Astellas Pharma Inc., Tokyo, Japan) as well as 
immunotherapeutic approaches [148].  
Patients diagnosed with breast/colon cancer, lymphoma, leukemia or melanoma have 
demonstrated spontaneous anti-Survivin T-cell reactivity [155] providing compelling evidence 
that Survivin could be recognized as a ‘non-self’ protein in cancer patients mounting an 
immune response against it [156]. Thus, Survivin renders a potential vaccination target 
against cancer [157], as autologous cytotoxic T lymphocytes (Survivin directed) activated 
with Survivin-primed dendritic cells or Survivin peptides are now being used in phase I trials 
in recurrent oral/colorectal cancer [158, 159], myeloma [160] and malignant melanoma [161].  
Apart from a feasible therapeutic target, Survivin renders a diagnostically relevant prognostic 
marker [148] associated with more aggressive clinicopathologic features along with a higher 
likelihood of tumour recurrence and reduced disease-free survival rates [59, 148, 162].   
 
1.5 Aim of project 
The aim of this project was to further examine the role of Survivin in radiation survival of 
tumour cells with respect to clonogenic survival, apoptosis, cell cycle regulation, cell motility 
and DNA damage response. The course of action involved the development of specific 
Survivin deletion and phosphorylation mutants followed by their functional characterization.  
The deletion mutants created were the XIAP, MicTub, Hsp90 and BIR lacking the XIAP, 
Microtubules, Hsp90 binding sites and BIR domain of the protein, respectively (Figure 3), 
whereas the phosphorylation sites S20, T34 and T117 of Survivin were mutated to Alanine 
(kinase-dead) S20A, T34A, T117A or to Aspartic acid S20D, T34D and T117D (phospho-
mimetics). The mutants were subsequently inserted into a C-terminal expression vector, 
namely the pEGFP (enhanced green fluorescent protein). The EGFP- tagged deletion as well 
Introduction 16  
 
as phosphorylation constructs along with the corresponding Survivin-EGFP wild type (wt) 
and empty vector (pEGFP) control were then used to stably transfect the human colorectal 
cancer cell line SW480. The cells stably expressing the Survivin-EGFP fusion constructs 
were then subjected to various functional assays including more physiological three-
dimensional (3D) clonogenic radiation survival assays, conventional 2D and more 
physiological 3D immunofluorescence staining of H2AX/53BP1 foci used as markers for 
DNA DSBs, invasion/transmigration assays, cell cycle analysis (flow cytometry), apoptosis 
(caspase 3/7) assays as well as co-immunoprecipitation assays following subcellular 
fractionations. 
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2. Materials and Methods 
2.1 Materials 
 
2.1.1 Appliances/Instruments 
 
Appliance Model/Description Company 
 
Agarose-  peQLab Biotechnologie GmbH, 
Gel electrophoresis-  Erlangen 
chamber   
 
Linear Accelerators SL-15 Elekta, Crawley, UK 
 
Electrophoresis chamber,  
Glass plates, Combs   Bio-Rad Laboratories, Munich 
   
ELISA Reader VIKTORTM 1420 Multilabel Counter Wallac, Waltham, MA, USA 
 Software: Wallac 1420n Manager  
 
Developer Optimax Typ TR HS Laborgeräte, Wiesloch 
 
Flow Cytometer FACSCalibur  Becton DICKINSON, Heidelberg 
 Software: Cell Quest Pro 
 
Water bath Gesellschaft für Labortechnik, 
GmbH, Burgwedel  
 
IKA® Shaker MTS 4  IKA Labortechnik, Staufen 
 
Incubator HERA cell 240+240i Thermo Fisher Scientific, Dreieich  
 
Microscope AxioImager Z1 Zeiss, Jena 
 Axio Vision Imager Softwear 4.6 
 
pH Meter pH Meter 765 Calimatic Knick, Berlin 
 
Photometer Bio Photometer Eppendorf, Hamburg 
 
Shaker-Incubator ES-20     BioSan, Riga, Lettland 
 
 
Laminar flow hood HERA safe Thermo Fisher Scientific,  
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  Dreieich 
 
Thermocycler Primus 96 advanced PEQLab Biotechnologie GmbH, 
      Erlangen    
Semi-Dry Transblot SD Bio-Rad Laboratories, München 
Transfer Cell  
 
Centrifuges  mini Spin Eppendorf, Hamburg  
 UNIVERSAL 320R Hettich, Tüttlingen 
 Eppendorf 5810 Eppendorf, Hamburg 
 
Note: The mini Spin is a tabletop centrifuge (suitable for 1.5 ml and 2 ml microcentrifuge 
tubes only) with a rotor radius of 6 cm. The UNIVERSAL 320R is a benchtop centrifuge with 
a rotor radius of 85 mm for 1.5 ml and 2 ml microcentrifuge tubes and another rotor with a 
radius of 141 mm for 15ml and 50ml tubes. In this work, all the room temperature 
centrifugation steps of microcentrifuge tubes were performed in the mini Spin centrifuge, 
while all the 4°C centrifugation steps were performed in the UNIVERSAL 320R. 
 
 
2.1.2 Consumables 
 
Description Company 
 
8 Stripwell™ Plates,  Corning Inc., NY, USA 
Flat Bottom, Certified High Binding 
 
96 Well micro-plates Greiner Bio-One, Frickenhausen 
 
100 mm cell culture dishes Sarstedt AG & Co, Nümbrecht 
 
60 mm cell culture dishes Sarstedt AG & Co, Nümbrecht 
 
AmershamTM HyperfilmTM ECL  GE Healthcare, BKM, UK 
High performance chemiluminescence film 
 
Blotting membranes GB003 VWR, Darmstadt  
 
AmershamTM-HybondTM-ECL GE Healthcare, BKM, UK 
 
Culture slides 8 chambers BD FalconTM, Eremodegem, Belgium 
 
CELLSTAR® 6-well cell culture plates Greiner Bio-One, Frickenhausen 
 
CELLSTAR® 12-well cell culture plates  Greiner Bio-One, Frickenhausen 
 
CELLSTAR® 24-well cell culture plates  Greiner Bio-One, Frickenhausen 
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CELLSTAR® Filter Top cell culture flasks  Greiner Bio-One, Frickenhausen 
 
Cloning Cylinders SciencewareR, Pequannock, NJ, USA 
 
Cover foil, Easy seal (80x140 mm) Greiner Bio-One, Frickenhausen 
 
Culture slides 8 Chambers BD FalconTM, Erembodegem, Belgium 
 
15ml tubes Greiner Bio-One, Frickenhausen 
 
50ml tubes Greiner Bio-One, Frickenhausen 
 
Filter paper Whatman, Kent, UK 
 
Fuji Medical X-Ray Film / Super RX Fujifilm Holdings Corporation,Dusseldorf 
 
Microscopic Slides Thermo Fisher Scientific, Dreieich 
 
Microscope Cover Glasses (24x60mm)  Marienfeld, Nordrhein-Westfalen 
 
Microscope Cover Glasses (18x18mm) Marienfeld, Nordrhein-Westfalen  
 
Polystyrene Round-Bottom tubes (14ml) Beckton Dickinson, NJ, USA 
 
Reaction tubes (1.5 ml)  Sarstedt AG & Co Nümbrecht 
 
Reaction tubes (2 ml)  Sarstedt AG & Co Nümbrecht 
 
FACS tubes, flow cytometry  Sarstedt AG & Co, Nümbrecht 
 
Pipette-tips, TipOne®, Graduated,  
Filter Tips STARLAB GmbH, Hamburg 
 
Pipette-tips, TipOne®, Graduated, 
Blue/Yellow/White STARLAB GmbH, Hamburg 
 
Pipette-tips with wide aperture STARLAB GmbH, Hamburg  
 
Counting Chamber Slides, Fast read 102TM Immune-systems, Paignton, UK 
Glass beakers SCHOTT AG, Mainz 
Insulin syringes B.Braun AG, Melsungen 
FACS tubes Sarstedt AG & Co, Nümbrecht 
BD BioCoatTM MatrigelTM Invasion Chamber BD Biosciences, Heidelberg 
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2.1.3 Chemicals and Media 
 
The standard chemicals were obtained from AppliChem GmbH (Darmstadt, Germany), 
ROTH ® (Karlsruhe) and SIGMA-ALDRICH ® (Munich). 
 
Description Company 
   
4′.6-Diamidin-2-phenylindol (DAPI) Molecular Probes, Eugen, OR, USA 
 
3D IrECM (Cultrex™) AMS Bio, Abingdon, UK 
 
Agarose ROTH®, Karlsruhe 
 
Albumin Fraction V (pH 7) AppliChem GmbH, Darmstadt 
 
Ammonium peroxodisulfate (APS) ROTH®, Karlsruhe  
 
Adefo Citroline 2000 (Developer) ADEFO-CHEMIE GmbH, Dietzenbach 
 
Adefofix (Fixer) ADEFO-CHEMIE GmbH, Dietzenbach 
 
Bromophenol blue AppliChem GmbH, Darmstadt 
 
Bovine Serum Albumin (BSA) AppliChem GmbH, Darmstadt 
 
Dichloroacetic acid (DCA) AppliChem GmbH, Darmstadt  
 
Deoxynucleotides (dNTP) Mix (high conc.) New Englands Biolabs Inc, Frankfurt 
 
Dulbecco´s Phosphate Buffered Saline (PBS) PAA Laboratories GmbH, Pasching,   
 Austria 
Dulbecco's Modified Eagle Medium (DMEM) InvitrogenTM, Darmstadt 
 
Dithiothreitol (DTT) SIGMA-ALDRICH®, Hamburg 
 
Ethanol SIGMA-ALDRICH®, Hamburg 
 
Ethylenediaminetetraacetic acid (EDTA) AppliChem GmbH, Darmstadt 
 
Ethidium bromide (EtBr) ROTH®, Karlsruhe 
 
FACSFlow Becton DICKINSON, Heidelberg 
 
Materials and Methods 21 
 
Foetal Calf Serum Gold (A15-151) PAA Laboratories GmbH, Pasching,  
  Austria 
Geneticin (G418)  Applichem GmbH, Darmstadt 
 
Glycine Applichem GmbH, Darmstadt 
 
Glycerine ROTH®, Karlsruhe 
 
HaltTM Protease Inhibitor Single-Use Cocktail Thermo Fisher Scientific, Dreieich  
 
Hydrogen chloride (HCl) AppliChem GmbH, Darmstadt 
 
Isopropanol SIGMA-ALDRICH®, Hamburg 
 
Kanamycin ROTH®, Karlsruhe 
 
Lysogeny broth (LB) medium ROTH®, Karlsruhe 
 
LB agar ROTH®, Karlsruhe 
 
Methylene blue C.I. 52015 AppliChem GmbH, Darmstadt 
 
Methanol SIGMA-ALDRICH®, Hamburg 
 
Milk Powder ROTH®, Karlsruhe 
 
RNAse/DNase-free water InvitrogenTM, Darmstadt 
 
Rubidium Chloride SIGMA-ALDRICH®, Hamburg 
 
Sodium Hydroxide (NaOH) SIGMA-ALDRICH®, Hamburg 
 
Sodium Chloride (NaCl) SIGMA-ALDRICH®, Hamburg 
 
Sodium dodecylsulfate (SDS) ROTH®, Karlsruhe 
 
Non Reducing Lane Marker, Sample Buffer Thermo Fisher Scientific, Dreieich 
 
OPTI-MEM® InvitrogenTM, Darmstadt 
 
Penicillin / Streptomycin (5 U ml-1) InvitrogenTM, Darmstadt 
 
Pierce® ECL, Western Blotting Substrate Thermo Scientific, Karlsruhe 
 
Ponceau S AppliChem GmbH, Darmstadt 
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ProSieve® QuadColor™ Protein Marker Lonza, Cologne 
 
Propidium Iodide InvitrogenTM, Darmstadt  
 
Protein G Agarose Beads P7700  SIGMA-ALDRICH®, Hamburg 
 
RestoreTM Western Blot Stripping Buffer Thermo Scientific, Karlsruhe 
 
Ribonuclease A (RNase A; 100 mg ml-1) QIAGEN, Hilden 
 
Roti-Fect PLUS ROTH®, Karlsruhe 
SDS-Solution (20 %) 
Rotiphoresis gel 30 ROTH®, Karlsruhe 
 
SDS-Pellets ROTH®, Karlsruhe 
 
Triton X-100 AppliChem GmbH, Darmstadt 
 
Sepharose A/G Protein Beads GE Healthcare, Buckinghamshire, UK 
 
Silicon for cloning cylinders Momentive performance materials,  
 Albany, NY, USA 
Tetramethylethylenediamin (TEMED) ROTH®, Karlsruhe 
 
Trypan Blue Stain 0.4 % InvitrogenTM, Darmstadt 
 
Trypsin/Ethylene diamine tetraacetic acid InvitrogenTM, Darmstadt 
(EDTA, 0.25 %)  
 
Tween® 20 AppliChem GmbH, Darmstadt 
 
Tris hydroxymethyl aminomethane (Tris) ROTH®, Karlsruhe 
 
Triton X-100 AppliChem GmbH, Darmstadt 
 
Vectashield® Mounting Medium Vector, Burlingame, CA, USA 
 
 
2.1.4 Solutions and Buffers 
 
4′.6-Diamidine-2-phenylindole (DAPI)-Staining 
 
DAPI concentration 300 ng/ml 
Fixing Solution 3.7% Formaldehyde in PBS 
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Triton X-Solution 0.25% Triton X-100 in PBS 
 
Cell Lysis 
 
Radio-Immunoprecipitation Assay (RIPA)-Buffer  
 
RIPA-Buffer (10x) 150 mM NaCl 
 50 mM Tris, pH 8.0 
 1 % Triton X-100 
 0.5 % Dichloroacetic acid (DCA) 
 0.1 %  SDS 
 
 
Polyacrylamide Gel Electrophoresis and Western Blot 
 
1M Tris HCl (pH 8.8) 60.6 g Tris 
 Adjust volume to 500 ml with distilled water  
 pH 8.8 with HCl  
 
Electrophor. Buffer 25.0 mM Tris 
 191 mM Glycine 
 3.47 mM SDS 
 Adjust volume to 1 L with distilled water 
 
TBS (10x) 87.7 g NaCl 
(pH 7.5) 12.1 g Tris 
 Adjust volume to 1 L with distilled water 
 
TBS-T 100 ml TBS (10x) 
(pH 7.5) 0.1 % Tween 20 
 Adjust volume to 1 L with distilled water 
 
Milk Powder Solution 5 % (w/v) Milk powder in TBS-T 
 
Ponceau  65.7 µM Ponceau S 
 37.5 ml Trichloroacetic acid (TCA) 
 Adjust volume to 250 ml with distilled water 
 
Reducing  
Electrophoresis  
Buffer 5 ml 50% Glycerol 
 0.9255 g 0.6 M DTT (Mr = 154.25) 
 1.028 g 10.28% SDS 
 3.5 ml 0.35 M Tris pH6.8 
 1.2 mg 0.012% Bromophenol bleu 
Materials and Methods 24 
 
 Adjust volume to 10 ml with distilled water, 2 ml aliquots (-20°C) 
 
Transfer Buffer 3.03 g Tris 
 12.1 g Glycine 
 20 % Methanol 
 0.05 % SDS 
 Adjust volume to 1 L with distilled water 
 
TAE (Tris-acetate) 
Buffer 50x 242 g Tris in 500 ml distilled water 
 100 ml 0.5 M Na2EDTA (pH 8.0) 
 57.1 ml glacial acetic acid 
 Adjust volume to 1 L with distilled water 
 
LB medium 20 g LB medium 
 1 L distilled water 
 
LB agar plates 35g LB agar 
 1 L distilled water 
 
DNA loading dye 
5x Blue Run (AGS) 
for 10 ml 0.25 ml 1 M Tris/HCl pH 7 
 3 ml 0.5 M EDTA 
 5 mg Bromophenol bleu 
 2.5 ml Glycerol 
 4.25 ml distilled water  
 
Table 1: Pipetting scheme for two discontinuous SDS-Electrophoresis gels (8.3 cm x 7.3 cm 
x 1 mm) 
 
 
Separation gel 
10 % 
Separation gel 
12 % 
Collection gel 
5 % 
Distilled Water 4.7 ml 3.6 ml 5.5 ml 
Rotiphoresis Gel 30 5.4 ml 6.5 ml 836 µl 
Tris HCl (pH 8.8) 6.0 ml 6.0 ml - 
Tris HCl (pH 6.8) - - 626 µl 
10 % SDS 162 µl 162 µl 50 µl 
20 % APS 54 µl 54 µl 40 µl 
TEMED 12 µl 12 µl 5 µl 
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2.1.5 Antibodies 
Table 2: Characteristics of primary antibodies used for western blotting, immunoprecipitation 
and immunofluorescence staining assays 
 
Antibody Host 
Under
-class 
Stock 
Solution 
[µg ml
-1
] 
Dilution 
Molecular 
weight 
[kDa] 
Company 
Catalogue 
number 
Anti-β-
Actin 
rabbit IgG 1000 1:10 000 42  
SIGMA-
ALDRICH, 
Hamburg 
A5441 
Anti-Lamin 
B1 
mouse 
IgG1-
Kapp
a 
200 1:200 68 MBL, MA, USA JM-3046-100 
Anti-
Calnexin 
mouse IgG 250 1:500 90 
BD 
Biosciences, 
NJ, USA 
610524 
Anti-
Survivin 
rabbit IgG 200 1:750 16.5  
R&D Systems, 
Heidelberg 
AF886 
Anti-
phospho-
H2A.X 
(Ser139) 
mouse IgG1 1000 1:1000 17 
Millipore, MA, 
USA 
05-636 
Anti-
53BP1 
rabbit IgG 1 1:1000 250  
Novus 
Biologicals, UK 
NB100-304 
Anti-GFP mouse IgG 2000 1:1000 27  
Abcam, 
Cambridge, UK 
Ab1218 
Anti-GFP rabbit IgG 2000 1:1000 27  
Abcam, 
Cambridge, UK 
Ab290 
Anti-DNA-
PKcs 
mouse IgG 500 1:250 450 
BD 
Biosciences, 
NJ, USA 
556456 
Anti-DNA-
PKcs 
rabbit IgG 200 
1:1000/ 
1:100 
469 
Abcam, 
Cambridge, UK 
Ab70250 
Isotype 
Control  
rabbit IgG 2500 1:100 - 
Cell Signaling, 
MA, USA 
3900 
Isotype 
Control 
mouse IgG 2500 1:100 - 
Cell Signaling, 
MA, USA 
5415 
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Table 3: Characteristics of secondary antibodies used for immunofluorescence staining 
 
Antibody Host 
Under
-class 
Stock 
Solution 
[mg ml
-1
] 
Dilution Label Company  
Catalogue 
number 
Anti-sheep 
IgG  
donkey IgG 2 1:250 
Alexa Fluor
R
 
488 
Molecular 
Probes, USA  
A-11015 
Anti-sheep 
IgG  
donkey IgG 2 1:250 
Alexa Fluor
R
 
594 
Molecular 
Probes, USA  
A-11016 
 
 
Table 4: Characteristics of secondary antibodies used for western blotting 
 
2.1.6 Expression plasmids 
 
Survivin expression plasmids: 
pEGFP-N1 control plasmid, Clontech, Mountain View, CA, USA 
(EGFP = Enhanced Green Fluorescent Protein) 
 
pEGFP-N1-Survivin wt (wildtype); made by Dr. S. Hehlgans, C. Petraki, Molecular 
Radiobiology, University Hospital Frankfurt 
Coupled 
enzyme 
Specificity Host 
Under-
class 
Stock 
solution 
[µg ml
-1
] 
Dilution Company 
Catalogue 
number 
Horse radish 
peroxidase 
rabbit goat IgG 400 1:4000 Santa Cruz 
Biotechnology, 
Heidelberg 
Sc-2254 
Horse radish 
peroxidase 
mouse goat IgG 400 1:1000 Sc-2255 
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Figure 4: Plasmid map for pEGFP-N1-wild type Survivin. Plasmid map for pEGFP-N1-Survivin: The map of 
the 5158 bp long plasmid shows „open reading frames“ (in pink), „origins of replication“ (in black), promoters (in 
green), terminators (in brown), restriction sites (in blue), a resistance gene against Kan/Neo (in orange) and the 
EGFP reporter gene (in purple) as well as the BIRC5 gene which codes for Survivin. The plasmid map was 
created by PlasMapper. 
The pEGFP-N1 vector was used to generate the Survivin-pEGFP fusion constructs, and the 
plasmid map shows an example of the wild type Survivin-pEGFP (Figure 4).  
 
2.1.7 Specific small interfering RNA 
 
Survivin specific small interfering RNA (siRNA) 
Negative control siRNA QIAGEN, Hilden 
 
BIRC5 Survivin 3 siRNA (#s1458) Ambion, Austin, TX, USA 
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Sequence (5’  3’) Sense: GCAGGUUCCUUAUCUGUCAtt 
    Antisense: UGACAGAUAAGGAACCUGCag 
 
2.1.8 Commercial Kits 
 
Description Company 
 
Micro BCATM Protein Assay Kit Thermo Scientific, Karlsruhe 
 
PCR Mycoplasma Test Kit   AppliChem GmbH, Darmstadt 
 
QIAquick Gel Extraction Kit QIAGEN GmbH, Hilden 
 
QIAquick PCR Purification Kit QIAGEN GmbH, Hilden 
 
NucleoBond Xtra Midi Plus EF Macherey-Nagel GmbH &co. KG, Dueren 
 
QIAprep Spin Miniprep Kit (250) Qiagen GmbH, Hilden 
 
PCR clean-up NucleoSpinR Extract II Macherey-Nagel GmbH & co. KG, Dueren  
 
Nuclear Complex Co-IP Kit Active Motif, Belgium 
 
QuikChange II Site-Directed Agilent Technologies, La Jolla CA, USA 
Mutagenesis Kit   
 
Caspase-GloR 3/7 Assay Promega, WI, USA 
 
 
 
2.1.9 Enzymes and respective buffers 
 
Description Company 
 
PfuUltraR High-Fidelity DNA Polymerase Strategene, La Jolla, USA 
 
T4-DNA-Ligase New Englands Biolabs Inc, Frankfurt 
 
T4 DNA Ligase buffer 10x New Englands Biolabs Inc, Frankfurt 
 
Taq-DNA-Polymerase SIGMA Chemical Co, St. Louis, USA 
 
DpnI New Englands Biolabs Inc, Frankfurt 
 
KpnI New Englands Biolabs Inc, Frankfurt 
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XbaI New Englands Biolabs Inc, Frankfurt 
 
BamHI New Englands Biolabs Inc, Frankfurt 
 
EcoRI New Englands Biolabs Inc, Frankfurt 
 
ApaLI New Englands Biolabs Inc, Frankfurt 
 
FspI New Englands Biolabs Inc, Frankfurt 
 
NEB Buffer 10x New Englands Biolabs Inc, Frankfurt 
 
 
2.1.10 Electrophoresis Markers 
 
Description Company 
 
100bp DNA-Ladder InvitrogenTM, Gaithersburg, USA 
1kb DNA-Ladder InvitrogenTM, Gaithersburg, USA 
 
 
2.1.11 Oligonucleotides 
 
The melting temperature of all the oligonucleotides used was calculated according to this 
formula: Tm = 4°C x (G + C) + 2°C x (A + T) from Nelson and Brutlag, 1979. They were 
provided by Eurofins MWG Operon (Ebersberg, Germany). 
 
 
Primers for PCR cloning 
 
Primers for subcloning of Survivin from pc3-Survivin-GFP into pEGFP-N1 
 pEGFPC1-fw: GAT CAC TCT CGG CAT GGA C 
 pEGFPC1-rev: CAT TTT ATG TTT CAG GTT CAG GG 
 CMV-fw: CGC AAA TGG GCG GTA GGC GTG 
 pEGFPN1-rev: GTC CAG CTC GAC CAG GAT G 
Primers for amplification of Survivin and subcloning in pEGFP-N1/KpnI/BamHI 
 1-Surv-fw: gg-ggtacc-ggcggc-ATGGGTGCCCCGACGTTGC, KpnI, Tm = 68°C 
 
 2-Surv-rev: cg-ggatcc-cg-ATCCATGGCAGCCAGCTGCTC, BamHI, Tm = 68 °C 
 
Primers for Survivin S20A mutation 
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 5-S20A-fw: 5’-tcaaggaccaccgcatcgctacattcaagaactgg-3’, Tm = 79.27°C 
 6-S20A-rev: 5’-ccagttcttgaatgtagcgatgcggtggtccttga-3’, Tm = 79.27°C 
 
Primers for Survivin S20D mutation 
 7-S20D-fw: 5’-ctcaaggaccaccgcatcgatacattcaagaactggcc-3’, Tm = 78.97°C 
 8-S20D-rev: 5’-ggccagttcttgaatgtatcgatgcggtggtccttgag-3’, Tm = 78.97°C 
 
Primers for Survivin T34A mutation 
 9-T34A-fw: 5’-gctgcgcctgcgccccggagcgg-3, Tm = 81.67°C 
 10-T34A-rev: 5’-ccgctccggggcgcaggcgcagc-3’, Tm = 81.67°C 
 
Primers for Survivin T34D mutation 
 11-T34-fw: 5’-gggctgcgcctgcgacccggagcggatg-3’, Tm = 81°C 
 12-T34D-rev: 5’-catccgctccgggtcgcaggcgcagccc-3’, Tm = 81°C 
 
Primers for Survivin T117A mutation 
 13-T117A-fw: 5’-gccaagaacaaaattgcaaaggaagccaacaataagaagaaagaat-3’, Tm = 
78.02°C 
 14-T117A-rev: 5’-attctttcttcttattgttggcttcctttgcaattttgttcttggc-3’, Tm = 78.02°C 
 
Primers for Survivin T117D mutation 
 15-T117D-fw: 5’-gagccaagaacaaaattgcaaaggaagacaacaataagaagaaagaatttgagg-3’, 
Tm = 78.96°C 
 16-T117D-rev: 5’-cctcaaattctttcttcttattgttgtcttcctttgcaattttgttcttggctc-3’, Tm = 78.96°C 
 
Primers for Survivin XIAP mutation 
 
For the 5’ end of deletion mutants XIAP and BIR primers 19 and 20 were annealed and 
subsequently used for ligation reactions. 
 
 19- XIAP-fw: starts with a.a.1 to 14, KpnI C-ATG GGT GCC CCG ACG TTG CCC 
CCT GCC TGG CAG CCC TTT CTC - T XbaI 
 20- XIAP-rev: starts with a.a. 14 to 1, XbaI CTAGA- GAG AAA GGG CTG CCA GGC 
AGG GGG CAA CGT CGG GGC ACC CAT – GGTAC KpnI 
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 21-XIAP-39fw: starts with a.a.39,  XbaI GC-TCT AGA-GCC GAG GCT GGC TTC 
ATC CA, Tm = 66°C 
 For reverse primer see primer no. 2-Surv-rev 
Primers for Survivin BIR mutation 
 For BIR domain deletion for the 5’end refer to primers no. 19-XIAP-fw and 20-XIAP-
rev 
 22-BIR-fw: starts with a.a. 88, XbaI GC-TCT AGA-TCT GTC AAG AAG CAG TTT 
GAA GA, Tm =64°C 
 For reverse primer see primer no. 2-Surv-rev 
Primers for Survivin MicTub mutation 
 For fw primer see primer no. 1-Surv-fw 
 23-Mictub-rev: starts with a.a. 98 BamHI cg-ggatcc-AAG GGT TAA TTC TTC AAA 
CTG CTT, Tm = 64°C 
Primers for Survivin Hsp90 mutation 
 For fw primer see primer no. 1-Surv-fw 
 24-Hsp90-rev: starts with a.a. 78 XbaI GC-TCT AGA-TTT ATG TTC CTC TAT GGG 
GTC G,Tm = 64°C 
 For the amplification of the 3’end of Hsp90 deletion mutant primer no. 22-BIR-fw and 
2-Surv-rev were used 
Primers for sequencing 
 37-CMV-fw-1: CGTAACAACTCCGCCCCATTG, Tm = 66°C 
 38-pEGFPN1-rev-1: CTTGTGGCCGTTTACGTCGC, Tm = 64°C 
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2.2 Methods 
 
2.2.1 Cell culture 
The human colorectal carcinoma cell line SW480 was obtained from the American Type 
Culture Collection (ATCC, Promochem, Germany). Cells were cultured in Dulbecco’s 
Modified Eagle Medium containing glutamax-I (L-alanyl-L-glutamine) and supplemented with 
10% foetal calf serum, 50 U/ml penicillin and 50 µg/ml streptomycin at 37°C in a humidified 
atmosphere containing 5% CO2. Cells were passaged on average 1:6 every 3 to 4 days 
using 2 ml trypsin after being washed with PBS (see 2.1.3 chemicals and media section) and 
plated on T-75 flasks with 12 ml of the medium mentioned above. In the case of the Survivin-
EGFP constructs 750 µg/ml of G418 was added to the medium.   
For 3D cell cultures, cells were plated into a mixture of 0.5 mg/ml laminin-rich extracellular 
matrix (lrECM; Cultrex 3D Culture Matrix BME Reduced Growth Factor Basement Membrane 
Extract; R&D Systems, Wiesbaden, Germany) and DMEM medium as previously described, 
on either 96-well plates (for 3D colony forming assays) or 24-well plates (for 3D lysates and 
3D immunofluorescence staining assays).  
 
2.2.2 Survivin constructs and stable transfection  
For expression of Survivin-EGFP fusion constructs human Survivin cDNA was amplified with 
specific primers (listed in section 2.1.11), flanked with KpnI and BamHI restriction sites, from 
an expression plasmid provided by R.H. Stauber (University Hospital of Mainz, Germany). 
Subsequently, the PCR fragments were digested with appropriate restriction enzymes (see 
section 2.1.9) and were inserted into KpnI/BamHI sites of the pEGFP-N1 expression vector. 
For deletion mutants, cDNA fragments left and right from the deletion were amplified by PCR 
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and ligated using the XbaI restriction site while inserted into the KpnI/BamHI restriction sites 
of the pEGFP-N1 vector. The phospho-mutants were generated using the site-directed 
mutagenesis kit (section 2.1.8) according to manufacturer’s guidelines using the primers 
listed in section 2.1.11.  
PCR for amplification of Survivin cDNA for subcloning in pEGFP-N1 
pc3-Surv-GFP was used as a template at a working concentration of 50 ng/µl along with (per 
reaction): 30µl 10 x Buffer, 7.5 µl of 10µM primers 1 and 2, respectively (for primer names 
see section 2.1.11), 7.5 µl of 10 mM dNTPs, 229.5 µl RNase/DNase-free water and 6 µl 
PfuUltra HF. The PCR conditions were as follows: 2 min 95°C, 35 x (30 s 95°C, 1 min 62°C, 
1 min 72°C), 15 min 72°C, 4°C. The samples were purified using the QIAquick PCR 
Purification Kit following manufacturer’s instructions. 
Restriction enzyme digestion of Survivin PCR fragment and pEGFP-N1 
For restriction enzyme digestion 10 µg of the pEGFP-N1 plasmid or 10 µg of the Survivin 
PCR fragment were used for digestion with: 3 µl KpnI + 3 µl BamHI + 1 µl BSA + 10 µl 
NEBuffer #1. The reaction volumes were adjusted to 100 µl with RNase/DNase-free water. 
The samples were incubated overnight at 37°C. 
Gel Purification of plasmid pEGFP-N1 
50 ml of 1% agarose gel (supplemented with 3 µl EtBr) in TAE buffer was used (in a gel 
electrophoresis chamber) for the loading of 120 µl KpnI/BamHI linearized plasmid for gel 
electrophoresis at 80 Volts for 1 hour. The plasmid was then extracted using the QIAquick 
Gel Extraction kit following manufacturer’s instructions.  
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Ligation of Survivin with the pEGFP-N1 
Ligation reaction contained the plasmid DNA pEGFP-N1/KpnI/BamHI (2 µl), the insert 
Survivin/KpnI/BamHI (2 µl), T4 DNA Ligase (1µl), 10 x T4 DNA Ligase Buffer (NEB) (1 µl) 
and RNase/DNase-free water (4 µl), followed by overnight incubation at 14°C.   
PCR for Survivin-EGFP deletion mutants 
Survivin cDNA was used as a template at a 50 ng/µl working concentration. For the PCR 
reaction forward and reverse primers (for primer names see section 2.1.11) (number 21/2 for 
XIAP right, 22/2 for BIR right, 1/28 for MicTub left, 1/24 for Hsp90 left and 22/2 for 
Hsp90 right) at a working concentration of 10 µM (1.25 µl each primer per reaction), 10x 
NEBuffer (5 µl per reaction), dNTPs 10 mM (1.25 µl per reaction), RNase/DNase-free water 
(38.25 µl per reaction) and PfuUltra HF (1 µl per reaction) were added. The PCR conditions 
were as follows: 2 min 95°C, 35 x (30 s 95°C, 1 min 62°C, 1 min 72°C), 15 min 72°C, 4°C. 
Agarose gel analysis followed (via agarose gel electrophoresis).  
Restriction enzyme digestion of Survivin deletion mutants PCR fragments 
45 µl of each PCR reaction was digested with 3 µl of each restriction enzyme + 10 µl 
NEBuffer #2 or #3 (XIAP right: XbaI/BamHI/#3, BIR right: XbaI/BamHI/#3, MicTub left: 
KpnI/BamHI/#3, Hsp90 left: KpnI/XbaI/#2, Hsp90 right: XbaI/BamHI/#3) + 1 µl BSA + 38 µl 
RNase/DNase-free water. The samples were incubated overnight at 37°C.  
PCR clean-up 
Samples were purified using the PCR clean-up NucleoSpinR Extract II kit following 
manufacturer’s protocol. 
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Ligation reactions for Survivin deletion mutants 
XIAP: 2µl pEGFP-N1/KpnI/BamHI, 1µl annealed primers 19 and 20/KpnI/XbaI, 2 µl Surv. 
XIAP right/XbaI/BamHI, 1 µl T4 DNA Ligase, 1 µl 10 x T4 DNA Ligase Buffer (NEB), 3 µl 
RNase/DNase-free water 
BIR: 2µl pEGFP-N1/KpnI/BamHI, 1 µl annealed primers 19 and 20/KpnI/XbaI; 2.5 µl Surv 
BIR right/XbaI/BamHI, 1 µl T4 DNA Ligase, 1 µl 10 x T4 DNA Ligase Buffer (NEB), 2.5 µl 
RNase/DNase-free water 
 MicTub: 2µl pEGFP-N1/KpnI/BamHI, 2 µl Surv MicTub left/KpnI/BamHI, 1 µl T4 DNA 
Ligase, 1 µl 10 x T4 DNA Ligase Buffer (NEB), 4 µl RNase/DNase-free water 
Hsp90: 2µl pEGFP-N1/KpnI/BamHI, 2.5 µl Surv BIR right/XbaI/BamHI, 3 µl Surv Hsp90 
left/KpnI/XbaI, 1 µl 10 x T4 DNA Ligase Buffer (NEB), 0.5 µl RNase/DNase-free water 
0.2 ml PCR tubes were used for the reactions which were incubated overnight at 14°C.  
Transformation 
50 µl of competent TOP10 E.coli stored with Rubidium Chloride were used for each 
transformation required (everything kept on ice). 3 µl of Dpn I digested DNA was added to 50 
µl bacteria (1.5 ml Eppendorf tubes were used) and the tubes were incubated for 20 minutes 
on ice before they were subjected to a heat shock at 42°C for 45 seconds and then placed 
back on ice for 2 minutes. Then, 250 µl of LB-Medium (warmed at 37°C) was added to each 
tube. All samples were incubated at 37°C for 1 hour while being shaked at 250 rpm. 
Subsequently, samples were centrifuged at 3,000 rpm for 3 minutes (RT). 200 µl of 
supernatants were removed and the pellets were resuspended in the medium that was left. 
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The samples were then spread on LB-covered dishes (with 50 µg/ml Kanamycin) and 
incubated overnight at 37°C followed by storage at 4°C.  
4 ml overnight culture of bacteria 
Using 50 ml tubes, 50 ml of LB medium was mixed with 50 µl of Kanamycin and each 4 ml of 
this mixture were transferred to 14 ml polystyrene round-bottom tubes (one tube per clone). 
Using a 200 µl pipette-tip, E. coli colonies were picked from the LB-covered dishes (following 
transformation) and were placed into the round-bottom tubes that were then overnight 
incubated at 37°C while being shaken at 250 rpm followed by plasmid mini-preparation.  
Plasmid mini-preparation 
After transformation of TOP10 bacteria and subsequent inoculation of selected colonies 
plasmid mini preparation was performed using the QIAprep Spin Miniprep kit following the 
manufacturer’s instructions. The solutions provided by the kit were the following: Buffer P1 
(for resuspension) contained 50 mM Tris/HCl, pH 8.0, 10 mM EDTA and 100 µg/ml Rnase A; 
buffer P2 (for lysis) contained 200 mM NaOH, 1% SDS; buffer N3 (for neutralisation) 
contained 3M KOAc, pH 5.5. Two ml from the content of each round-bottom tube (having 
been inoculated) were transferred to 2 ml Eppendorf tubes that were centrifuged at 5,000 
rpm (tabletop centrifuge) for 5 minutes (RT). Supernatants were discarded and 250 µl of 
buffer P1 was added in each pellet followed by vortexing. Then, 250 µl of buffer P2 was 
added to the tubes, the contents were mixed and 350 µl of buffer N3 was also added to each 
tube, mixed and centrifuged at 13,000 rpm (tabletop centrifuge) for 10 minutes (RT). All 
supernatants (now containing plasmid-DNA) were transferred to Qiaprep spin columns and 
centrifuged at 13,000 rpm for 1 minute; all eluates were discarded. The columns were 
washed with 0.5 ml buffer PB (provided by the kit) and centrifuged at 13,000 rpm for 1 
minute; eluates were discarded. The columns were washed again this time with 0.75 ml 
buffer PE and centrifuged at same settings; eluates were discarded. The empty columns 
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were dry-centrifuged at the same settings. Subsequently, the columns were placed in new 
1.5 ml Eppendorf tubes when 50 µl of buffer EB (for elution – containing 10 mM TrisCl, pH 
8.5) was added to each of the column, incubated for 1 minute and centrifuged at same 
settings. The concentration was measuered in an Eppendorf Biophotometer (diluting each 
plasmid DNA 1:100 with water).  
Plasmid midi-preparation   
When certain clones per construct were confirmed by sequencing (Eurofins, MWG Operon), 
they were followed by midi preparation using the NucleoBond Xtra Midi Plus EF kit according 
to manufacturer’s guidelines. Prior to preparation, the according inoculation was first carried 
out. In detail, in a 500 ml glass beaker, 100 ml of LB medium was supplemented with 50 
µg/ml Kanamycin and inoculated with 100 µl overnight cultures (dilution 1:1000) at 37°C and 
175 rpm shaking. On the following day, 50 ml of each of these cultures were transferred to 
50 ml tubes. The bacteria were pelleted by centrifugation at 4,000 rpm for 15 minutes at 4°C. 
Supernatants were discarded and 8 ml of RES-EF (provided by the kit) was used for 
resuspension. Eight ml of Lys-EF was added, mixed and incubated at RT for 5 minutes. 8 ml 
of NEU-EF was then added, mixed and incubated on ice for 5 minutes. Subsequently, 15 ml 
of EQU-EF was carefully added to the column filters and the lysates were then mixed and 
poured into the columns which were then washed with 5 ml FIL-EF before the paper filters 
were removed. The columns were washed with 35 ml ENDO-EF followed by washing with 15 
ml WASH-EF before they were put in new 50 ml tubes in order to elute the plasmid-DNA with 
5 ml ELU-EF. The columns were removed; 3.5 ml of Isopropanol was added to the eluates, 
mixed and incubated at RT for 2 minutes before they were syringed through a NucleuoBond 
Finalizer in a 30 ml-syringe twice and washed 1 x with 2 ml 70% EtOH (Endotoxin-free from 
kit). Then, the NucleoBond Finalizer was placed in a 1 ml-syringe and 0.5 ml H2O-EF was 
used to collect the eluate in 1.5 ml Eppendorf tubes. Concentrations were determined using 
a Bio photometer.  
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Stable transfection  
Prior to stable transfection, the constructs were linearized using 30 µg of plasmid DNA, 10 µl 
of 10 x NEBuffer, 4 µl of ApaLI enzyme (10 U/µl), 1 µl BSA and the volumes were adjusted to 
100 µl with RNase/DNase-free water while the reactions were set up in 1.5 ml tubes 
incubated overnight at 37°C. After the confirmation of the linearization via agarose gel 
electrophoresis, the linearized plasmids were subjected to PCR clean-up using the 
NucleoSpin Extract II kit following manufacturer’s instructions. SW480 cells were then stably 
transfected with pEGFP-N1 or Survivin-EGFP expression constructs using 4 µg linearized 
plasmid DNA diluted in serum free Opti-MEM and Roti-Fect PLUS transfection reagent 
according to manufacturer’s instructions (see section 2.2.3 for method of transfection). 
Following transfection, the cells were transferred from 6-well plates to 100 mm petri dishes 
where colonies were allowed to grow in DMEM + 10% FCS +1% P/S enriched with 750 µg/ml 
G418 for selection. Clones were isolated using cloning cylinders embedded in silicon while 
expression of EGFP or Survivin-EGFP constructs was verified by fluorescence microscopy 
and Western blotting.  
Selection of fluorescent colonies 
When the 100 mm petri dishes (mentioned above) contained colonies large enough to be 
visible by naked eye, the dishes were washed with PBS and transferred to a fluorescence 
microscope where fluorescent colonies were selected and marked (from the outside of the 
dish). The dishes were then taken under laminar flow hood where silicon-embedded cloning 
cylinders were carefully placed on the selected colonies and 60 µl of trypsin was added to 
each cloning cylinder for trypsinization (5 minutes incubation at 37°C/5%CO2 under sterile 
conditions). The cells were then resuspended in the cylinders, with 60 µl of DMEM + 10% 
FCS +1% P/S and transferred in 12-well plates (one clone per well) along with 1 ml medium 
(DMEM + 10% FCS +1% P/S + 750 µg/ml G418) per well. They were then left in those 12-
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well plates to grow to approximately 60-80% confluence before their transfer to T-25 flasks. 
Cells from T-25 flasks were later (when 80-100% confluent) harvested for cryostocks.  
Fluorescence imaging 
Fluorescence images of stably transfected cells were obtained using an Axiovert 40 CFL 
microscope (Carl Zeiss, Göttingen, Germany) after staining the nuclei with 4’,6-diamidino-2-
phenylindole (DAPI). 
 
2.2.3 Attenuation of endogenous Survivin via siRNA 
For the knockdown of endogenous Survivin, an siRNA targeting the 3’-untranslated region of 
Survivin was used: Surv. siRNA: 5’- GCAGGUUCCUUAUCUGUCAtt-3’ (sense), siRNA ID 
s1458. The non-specific negative control siRNA was from Qiagen. 24 hours after plating 3.5 
x 105 cells of each of the Survivin-EGFP constructs on 6-well plates, both of the siRNAs were 
diluted in serum free Opti-MEM to obtain a final concentration of 20 nM, in this case 2.5 µl 
siRNA (10µM) plus 122.5 µl Opti-MEM calculated for each well. Roti-Fect PLUS transfection 
reagent was used under serum-free conditions at a concentration of 20 nM. Thus, Roti-Fect 
was also diluted in serum free Opti-MEM (5 µl Roti-Fect plus 120 µl Opti-MEM calculated per 
well) and 5 minutes later it was mixed with the diluted siRNA and incubated for 20 minutes at 
RT. In the meanwhile, cells were washed once with PBS and 1 ml of serum free Opti-MEM 
was added. Subsequently, the siRNA/Opti-MEM solution was mixed with the Roti-Fect/Opti-
MEM solution, and 250 µl of the mixture was added to each well. The 6-well plates were 
incubated for 8 hours at 37°C, 5% CO2, followed by addition of 1.25 ml Opti-MEM/20% FCS 
to each well. The 6-well plates were incubated for 24 hours at 37°C 5% CO2 prior to any 
further experiments.        
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2.2.4 Irradiation procedure 
Irradiation of cells with single photon doses ranging from 2 to 6 Gy was performed using a 
linear accelerator (SL-15, Elekta, Crawley, UK) with 6 MeV/100 cm focus-surface distance 
and a dose rate of 4 Gy/min. Mock-irradiated cultures were kept at room temperature in the 
X-ray control room while the other samples were being irradiated. 
 
2.2.5 Three-dimensional colony forming assay 
 
 
Figure 5: Methodology for 3D radiation clonogenic survival assays. The procedure of a 3D radiation 
clonogenic survival assay is briefly depicted here on a symbolic time scale followed by a photograph of colonies 
taken under the microscope (2.5x). 
 
24 h after the knockdown of endogenous Survivin via siRNA transfection (Figure 5), the cells 
were washed with PBS (1 ml per well) and trypsinized (0.25 ml per well) in order to be 
counted with a chamber counter (1:2 dilution with trypan blue) under the microscope. Single 
cells were plated in 0.5 mg/ml lrECM/DMEM/10% FCS/1% penicillin/streptomycin on 96-well 
plates pre-coated with 50 µl 1% Agarose, by triplets (3 wells per construct per siRNA and 1 x 
103 cells per well) in 100 µl cell-matrigel mixture. 200 µl of PBS was added to the wells 
around those containing cells. The 96-well plates were incubated for 90 minutes at 37°C, 5% 
CO2, followed by addition of 100 µl of DMEM+10% FCS+1%P/S to each well. The plates 
were incubated at 37%, 5% CO2 for 24 hours until irradiation (0, 2, 4, 6 Gy) and cell colonies 
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(> 50 cells) were microscopically counted 7 days after plating (Figure 5). Plating efficiencies 
were calculated as numbers of colonies counted (0Gy) / numbers of cells plated. Surviving 
fractions were calculated as numbers of colonies counted / (numbers of cells plated × plating 
efficiency). Each point on survival curves represents the mean surviving fraction from 3-4 or 
more independent experiments. Survival variables α and β were fitted according to the linear 
quadratic equation SF = exp [−α x D − β x D2] with D = dose using EXCEL® software 
(Microsoft). The radiation-induced cytotoxicity enhancement factor at 50% cell survival was 
calculated by transforming the above mentioned equation using α and β values of the 
individual survival curves.  
 
2.2.6 Protein extraction and Western blotting 
Protein extraction from 3D cultures 
24 hours after the plating of mock- and siRNA-transfected cells in 0.5 µg/µl lrECM on 24-well 
plates pre-coated with 300 µl of 1% Agarose (1 x 106 cells per well), the matrigel was 
carefully removed and 130 µl of ice-cold RIPA (see section 2.1.4 solution and buffers) was 
added to each well and incubated on ice for 30 minutes. The RIPA/cells mixture was 
transferred from the 24-well plates to 2 ml Eppendorf tubes, incubated on ice for 10 minutes 
followed by passing through a 30-G insulin syringe to optimize protein extraction. The 
samples were then incubated on ice for 30 minutes, centrifuged for 15 minutes at 4°C 14,000 
rpm followed by transfer of supernatants to new 1.5 ml Eppendorf tubes. For the estimation 
of the lysate volume, all samples were filled with RIPA up to the same volume of that with the 
largest volume. Loading buffer was then added to all samples (1/5 of the volume of the 
largest volume-sample). The samples were then stored at - 80°C before Western blotting. 
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Western blotting 
Western blotting was performed in the following cases: to confirm the knockdown of 
endogenous Survivin, to confirm the correct sizes and expression of Survivin-EGFP mutants, 
their relation to other proteins as well as to identify immunoprecipitated complexes. For these 
reasons, 10% or 12% gels were prepared for the SDS-gel electrophoresis (see section 2.1.4 
table 1) where 20 - 30 µg of protein extract was loaded per lane. Prior to electrophoresis all 
samples were heated at 95°C for 10 minutes, shortly (1 minute) centrifuged at 11,000 rpm at 
4°C and during electrophoresis (25 mA 400V per gel) 1 L of electrophoresis buffer was used 
(see section 2.1.4 for buffers) in the chamber. Following gel-electrophoresis, the gels were 
placed on 7 x 9 cm filter papers (see section 2.1.2) soaked in transferring-buffer (see section 
2.1.4) then covered with blotting membranes (6 x 8 cm) followed by two more filter papers 
and transferred on a semi-dry blotting apparatus for protein transfer at 50 mA per gel for 150 
– 210 min. Following blotting, to confirm correct protein transfer and equal loading the 
membranes were soaked in Ponceau S solution for 1 minute, subsequently distained with 
distilled water and then blocked in 5% milk powder/TBS-T at room temperature for 30 
minutes until primary antibodies were applied that were diluted in 5% BSA/TBS-T prior to 
application and incubated with the respective membranes at 4°C overnight. The following 
primary antibodies were used (for more details see Table 2 and 4): anti-Survivin (AF886), 
Anti-Calnexin (BD610524), anti-GFP (ab290 and ab1218), anti-Lamin B1 (JM-3046-100), 
anti-DNA-PKcs (BD556456 and ab70250), anti--actin (A5441). For detection of proteins, 
horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse secondary 
antibodies (diluted in 5% milk powder/TBS-T) were used after 3 x washing of the membranes 
(using TBS-T). The membranes were then incubated with appropriate dilutions of secondary 
antibodies in 5% milk powder/TBS-T for 1 hour followed by 4 washing steps with TBS-T and 
one with TBS. The membranes were then incubated for 1 min with working solutions of 
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enhanced chemiluminescent (ECL) substrate (Thermo Scientific), placed in plastic sheet 
protectors and exposed to Hyperfilm ECL (GE Healthcare) prior to film development. 
 
2.2.7 Subcellular fractionation and immunoprecipitation  
Cytoplasmic and nuclear extracts were prepared with the Nuclear Complex Co-IP kit 
according to manufacturer’s protocol (all buffers hereby mentioned regarding fractionation 
were supplied by the kit) and subjected to co-immunoprecipitation experiments and western 
blotting as described.  
Subcellular fractionation 
Four million cells were plated per T-75 flask, and 4 x T-75 flasks were used per construct in 
order to be subjected to fractionation and eventually co-IP. On the second day after plating, 
serum starvation was performed, replacing the usual medium (DMEM/10% FCS/1% P/S) 
with serum-free medium (DMEM without FCS) in all T-75 flasks. On the day following the 
serum starvation, the flasks were washed with ice-cold PBS and scraped with 1 ml 5% 
Phosphatase Inhibitor/PBS. The scraped cells were transferred to pre-chilled 15 ml tubes 
that were centrifuged at 1,500 rpm at 4°C for 5 minutes. Supernatants were discarded and 
each pellet was resuspended in 500 µl ice-cold Hypotonic Buffer (containing Hypotonic 
buffer, Phosphatase Inhibitor, Protease Inhibitor and double distilled water) and incubated on 
ice for 15 minutes. 25 µl of detergent (provided by the kit) was then added in each sample, all 
of which were then centrifuged at 12,000 rpm at 4°C for 30 seconds. All cytoplasmic fractions 
were then transferred to 1.5 ml Eppendorf tubes properly labelled for the cytoplasmic 
fractions. The pellets were resuspended in 100 µl digestion buffer (containing 0.5% 100 mM 
PMSF, 98.5% digestion buffer, 1% Protease Inhibitor Cocktail) and 0.5 µl of enzymatic 
shearing cocktail was added to all samples before they were incubated at 4°C for 90 
minutes. Following incubation, 2 µl of 0.5M EDTA was added to each sample which were 
Materials and Methods 44 
 
then gently vortexed for 2 seconds and incubated for 5 minutes on ice before they were 
centrifuged at 12,000 rpm for 10 minutes. The supernatants were collected (i.e. the nuclear 
fractions) in new 1.5 ml Eppendorf tubes. Concentrations were determined using the Micro 
BCA assay kit according to manufacturer’s instructions. 
Immunoprecipitation    
For co-immunoprecipitation, 500 µg of nuclear extract (per sample) resuspended in 500 µl 
IP-Low buffer (included in the Nuclear Complex Co-IP kit) were incubated overnight at 4°C 
with anti-GFP (ab1218) or anti-DNA-PKcs (BD556456) antibodies. A mouse (G3A1) mAb 
IgG1 Isotype control antibody served as a control. The final concentration of all antibodies in 
the nuclear lysates was 2 µg/ml. Following overnight incubation, 50 µl of slurry protein G 
agarose beads (Sigma-Aldrich) was added to the samples and incubated at 4°C for 1 hour 
while gently being rotated. Then, the probes were centrifuged at 5,500 rpm for 2 minutes, 
supernatants were discarded and samples were washed 3 times with 500 µl IP-High buffer 
(included also in the Co-IP kit) and once with PBS at 5,500 rpm for 2 min at 4°C before 30 µl 
RIPA and 8 µl loading dye were added to the beads-pellet. The samples were heated for 10 
minutes at 95°C and centrifuged at 11,000 rpm for 50 sec prior to SDS-electrophoresis and 
eventually western blotting. 
 
2.2.8 Immunofluorescence staining and imaging  
Residual DNA double-strand breaks (DSB) of 3D and 2D cell cultures (plated on 24-well 
plates) were evaluated using the foci assay. 
Two-dimensional immunofluorescence staining 
24 hours after the knockdown of endogenous Survivin (via siRNA) on 6-well plates, cells 
were harvested and plated on 24-well plates with DMEM/10% FCS/1% P/S for 2D 
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immunofluorescence staining (IF). In detail, cover slips were placed on 24-well plates and 75 
x 103 cells were plated per well, for control siRNA and Survivin-targeted siRNA per construct. 
24 hours after plating, the cells were irradiated with 2 Gy and stained 40 minutes or 24 hours 
later (different plates were prepared for different time points) according to the time point of 
interest. Cells were then permeabilized and fixed using 0.25% Triton X-100 and 3.7% 
formaldehyde in PBS for 10 minutes at RT. Subsequently, blocking took place via incubation 
for 1 hour with 3% BSA in PBS followed by staining with anti-phospho-histone H2AX and 
anti-53BP1 antibodies 1:1000 diluted in 3% BSA in PBS for 1 hour (50 µl solution  per cover 
slip was used). Cells were then washed once with PBS and stained with secondary 
antibodies i.e. Alexa Fluor 594 goat anti-mouse and Alexa Fluor 488 goat anti-rabbit diluted 
1:500 (Invitrogen) for another hour in the dark, followed by 4’,6-diamidino-2-phenylindole 
(DAPI; Roth) staining for 5 minutes. Cover slips were then transferred on microscopic slides 
after being covered with one drop of Vectashield mounting medium. H2AX/53BP1 foci were 
microscopically counted from at least 50 cells per experimental condition.  
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Three-dimensional immunofluorescence staining 
  
Figure 6: Methodology of 3D IF of H2AX/53BP1 foci. The procedure of the 3D immunofluorescence staining of 
H2AX/53BP1 foci for evaluation of residual DNA DSBs is hereby represented on a symbolic time scale followed 
by a photograph of nuclei taken under the microscope (40x). Bar: 10µm 
 
24 hours after the siRNA-mediated attenuation of endogenous Survivin on 6-well plates 
(Figure 6), cells were harvested and plated on 24-well plates (pre-covered with 1% agarose) 
in a mixture of 0.5 mg/ml laminin-rich extracellular matrix and DMEM/10% FCS/1% P/S for 
3D IF. In detail, 0.5 x 106 cells were plated per well, for control siRNA and Survivin-targeted 
siRNA per construct. 24 hours after plating, the cells were irradiated with 2 Gy. 24 hours 
following irradiation, the cells were transferred with the matrigel from the 24-well plates to 1.5 
ml Eppendorf tubes and centrifuged for 3 minutes at 3,500 rpm (talbetop centrifuge). 
Supernatants were discarded and cells were permeabilized and fixed using 0.25% Triton X-
100 and 3.7% formaldehyde in PBS (200 µl solution per tube) for 15 minutes at RT. Then, 
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the samples were centrifuged again at 4,500 rpm for 3 minutes, supernatants were removed, 
and the pellets were resuspended in 50 µl blocking solution (3% BSA in PBS) and left to be 
blocked for 1 hour. Subsequently, staining took place with 10 µl (per sample) of 1:500 diluted 
in blocking solution anti-phospho-histone H2AX and anti-53BP1 (same dilution) antibodies 
for 2 hours. Cells were then washed once with PBS for 10 minutes, centrifuged at 4,500 rpm 
for 3 minutes and pellets were resuspended with 50 µl (per pellet) of 1:250 diluted in blocking 
solution secondary antibodies i.e. Alexa Fluor 594 goat anti-mouse and Alexa Fluor 488 goat 
anti-rabbit and incubated for another hour in the dark. The cells were then washed twice with 
1 ml PBS via resuspension followed by 10 minutes incubation and centrifugation at 4,500 
rpm for 3 minutes. The pellets were finally resuspended in 15 µl DAPI solution (300 ng/µl) 
and incubated in the dark for 5 minutes. The cell suspensions were then transferred on 
microscopic slides, along with one drop of Vectashield mounting medium on each sample 
while a square cover slip was used to seal the cells. H2AX and 53BP1 foci were 
microscopically counted from at least 50 cells per experimental condition (Figure 6). 
Fluorescence imaging 
Fluorescence images of H2AX and 53BP1 foci were obtained using an Axiovert 40 CFL 
microscope (Carl Zeiss).  
 
2.2.9 Cell cycle analysis  
24 hours after the siRNA-mediated knockdown of endogenous Survivin, cells were 
harvested, counted and 3.5 x 105 cells were plated in triplets on 6-well plates with 
DMEM/10% FCS/1% P/S for cell cycle analysis. 24 hours after plating, the supernatants from 
all samples were transferred to 15 ml tubes. The cells were then washed with 5 ml PBS and 
trypsinized in 1 ml trypsin for 5 minutes at 37°C/5% CO2. Cells were then resuspended in 3 
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ml medium and transferred in the 15 ml falcon tubes containing their supernatants. The tubes 
were then centrifuged at 1,000 rpm for 5 minutes, washed twice with 1 ml PBS, transferred to 
1.5 ml Eppendorf tubes and centrifuged at 3,000 rpm for 5 minutes. Pellets were 
resuspended in 200 µl PBS and 1 ml 70% EtOH (cooled at -20°C) was added to each 
sample. They were then centrifuged at 2,000 rpm at 4°C for 5 minutes, each pellet was 
resuspended in 100 µl PBS followed by addition of 100 µl RNase A (100 µg/ml in PBS) and 
100 µl propidium iodide (100 µg/ml in PBS). The samples were then incubated at 37°C for 30 
min. Cell suspensions were then transferred in FACS tubes that were measured (12,000 
events at 449 nm; FL2-585 Red) using the FACS Calibur flow cytometer and the 
CellQuestPro software (Becton Dickinson).  
 
2.2.10 Measurement of apoptosis and caspase 3/7 assay  
For quantification of apoptotic cells, subG1 content was analysed by flow cytometry as 
described in section 2.2.9. For quantification of caspase 3/7 activity a CASPASE GLOTM-
assay was used according to manufacturer’s instructions. In particular, 24 hours after the 
knockdown of endogenous Survivin (via siRNA on 6-well plates) cells were washed, 
trypsinized, counted and 6 x 103 cells were plated per well (in triplets per construct) on three 
96-well plates (two for 0 Gy and one for 6 Gy) with DMEM/10% FCS/1% P/S. 24 hours later, 
one of the 0 Gy plates was measured after removing 70 µl medium from each well and 
adding 30 µl substrate (Caspase-Glo® 3/7 Assay Reagent), then shaking at 300 rpm for 30 
seconds followed by 90 minutes incubation at RT. Measurement was conducted using an 
ELISA-Reader (Wallac Victor; Protocol: Luciassay 10sec). 24 hours thereafter, the two 
remaining plates (the other 0 Gy and the 6 Gy one) were treated and measured likewise.    
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2.2.11 Transmigration assay 
 
 
 
Figure 7: Methodology of transmigration assay. The procedure of a transmigration assay is hereby depicted 
along with the respective the time scale. 
 
For transmigration assays (Figure 7), knockdown cell cultures were washed with PBS, 
trypsinized, counted and single cells were plated in a BD BioCoat™ Matrigel™ Invasion 
Chamber under serum-free conditions (2.5 x 104 cells). After 24 h of cell attachment, serum-
containing medium used as a chemoattractant was added into the lower buffer chamber and 
the cells were further incubated at 37 °C/5% CO2 for 24 h. For analysis of transmigrated 
cells, the medium was removed from all wells and the inserts were cleaned from the inside 
with a cotton applicator in order to remove matrigel and non-invaded cells. The inserts were 
then transferred to another 24-well plate with 750 µl of 70% EtOH in each well for fixation, 
and were left there for 20 minutes. The inserts were then transferred to another 24-well plate 
with 750 µl PBS in each well for washing. Subsequently, the membranes of the inserts were 
removed using a scalpel and soaked in 50 µl of 300 ng/ml DAPI solution for 20 minutes at 
37°C (in the dark). Subsequently, the cells were placed on microscopic slides (cells-side on 
top) followed by mounting medium and the transmigrated cells were microscopically counted. 
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2.2.12 Data analysis  
Means  standard deviation (SD) were calculated with reference to controls defined in a 1.0 
scale. To test statistical significance, the two-sided unpaired Student´s t-test was applied 
using EXCEL® Microsoft software. Results were considered statistically significant if a p-
value of less than 0.05 was reached. 
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3. Results 
3.1 The impact of Survivin deletion mutants on cellular radiation response  
To analyse the impact of Survivin BIR domain as well as XIAP, Microtubules and Hsp90 
binding sites on three-dimensional radiation clonogenic survival, cell cycle distribution, 
radiation induced DNA double-strand break repair, apoptosis and transmigration, several 
Survivin constructs were established expressing the wild type protein [Surv. wt, comprised of 
amino acid residues amino acids (AA) 1-142], XIAP (XIAP; AA 1-14 and 39-142), 
Microtubules (MicTub; AA 1-98) or Hsp90 (Hsp90; AA 1-78 and 88-142) binding sites 
deletion mutants or a BIR domain deletion mutant (BIR; AA 1-14 and 88-142) fused in-
frame to EGFP at the carboxyterminus of the recombinant proteins (Figure 8). Subsequently, 
SW480 colorectal cancer cells were stably transfected and expression of Surv. wt and 
deletion mutants was confirmed by western blotting and fluorescence microscopy (Figure 9). 
pEGFP-N1 empty vector (EGFP) served as a control. 
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Figure 8: Symbolic diagram of Survivin-EGFP fusion constructs. Schematical representation of enhanced 
green fluorescent protein (EGFP), Survivin wild type-EGFP fusion protein (Surv. wt), Survivin XIAP binding site 
deletion mutant fused to EGFP (XIAP), Survivin baculovirus inhibitor of apoptosis protein (IAP) repeat (BIR) 
domain deletion mutant fused to EGFP (BIR), Survivin Microtubules binding site deletion mutant fused to EGFP 
(MicTub), Survivin heat shock protein (Hsp)90 binding site deletion mutant fused to EGFP (Hsp90). 
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a) 
 
b) 
 
Figure 9: Stable expression of Survivin deletion mutants in SW480 cells. (a) Western blot confirmation of 
expression of EGFP, Surv. wt, Surv. XIAP, Surv. BIR, Surv. MicTub, Surv. Hsp90 all of them fused to EGFP. 
Survivin and GFP antibodies were used to detect recombinant protein expression, β-actin served as loading 
control. (b) Fluorescence images of SW480 cells stably transfected with Survivin-EGFP expression constructs 
(green). Nuclei were stained with DAPI (blue). Bar: 10 µm. 
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3.1.1 Survivin BIR, XIAP, Microtubules and Hsp90 deletion mutants failed to 
reconstitute irradiation induced cell cycle arrest and apoptosis after knockdown of 
endogenous Survivin  
SW480 cells stably overexpressing Surv. wt and Survivin deletion constructs were subjected 
to siRNA-mediated knockdown of endogenous Survivin without affecting expression of 
recombinant Survivin-EGFP fusion proteins (Figure 10).  
 
 
Figure 10: Western blot analysis with cells overexpressing Survivin deletion mutants. Western blot 
confirmation of the expression of recombinant Survivin (the indicated Survivin-EGFP fusion constructs stably 
expressed by SW480 cells) along with confirmation of the siRNA-mediated knockdown of endogenous Survivin. 
Survivin and GFP antibodies were used to detect endogenous and recombinant protein expression, β-actin 
served as a loading control. M: Mock-treated cells; co: Control siRNA-treated cells; Surv: cells treated with siRNA 
targeted against endogenous Survivin 
 
Former studies have shown that Survivin attenuation (via siRNA) in colorectal cancer cells 
yielded an increased G2/M fraction of the cell cycle distribution 24 hours after knockdown, 
arresting the cells in a more radioresponsive phase of the cell cycle [127, 163]. In the present 
investigation, cell cycle analysis via flow cytometry performed with SW480 cells stably 
overexpressing the recombinant Survivin-EGFP fusion constructs confirmed a G2/M arrest 
and an increased SubG1 fraction upon knockdown of endogenous Survivin in EGFP control, 
Survivin XIAP, BIR, MicTub and Hsp90 mutant transfected cells as compared to mock 
or control siRNA treated cells (Figure 11, 12a).  
pEGFP
rec. Surv.-EGFP
endog. Surv. 
β-actin
M co Surv M co Surv M co Surv M co Surv M co Surv M co Surv siRNA
Surv. wt XIAP BIR MicTub Hsp90
Results 55 
 
 
 
 
Figure 11: Cell cycle analysis of SW480 cells overexpressing Survivin deletion mutants. Cell cycle analysis 
using SW480 cells stably expressing Surv. XIAP, Surv. BIR, Surv. MicTub, Surv. Hsp90, Surv. wt and the 
empty vector (for control) pEGFP. The experiments were conducted following siRNA-mediated knockdown of 
endogenous Survivin (Surv. si), along with control siRNA (co si) treated and mock treated (only transfection 
agent) cells that were used for controls. n=4; *P<0.05; **P<0.01 
 
By contrast, stable overexpression of recombinant Survivin wt rescued SW480 cells from the 
G2/M arrest induced by knockdown of endogenous Survivin. 
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a) 
b)  
 
 
Figure 12: Sub G1 fraction and caspase 3/7 activity assays of cells overexpressing Survivin deletion 
mutants. (a) Sub G1 fraction via flow cytometry using SW480 cells stably overexpressing Survivin-EGFP fusion 
constructs after attenuation of endogenous Survivin (via siRNA). Mock and control siRNA-treated cells were used 
as control. (b) Caspase 3/7 activity assay performed with SW480 cells stably transfected with Survivin-EGFP 
fusion constructs following knockdown of endogenous Survivin (via siRNA) and irradiation with 6Gy. Control 
siRNA-treated cells served as a control. n=4; *P<0.05; **P<0.01  
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Survivin promotes tumour cell survival in part by inhibiting caspases as it has been shown by 
previous studies where colorectal cancer cells following treatment with siRNA targeted 
against Survivin responded with an increased apoptosis and caspase 3/7 activity [59, 127]. In 
the present study, an elevated caspase 3/7 activity was observed upon knockdown of 
endogenous Survivin in the deletion mutant transfected cells in comparison with control 
siRNA treated cells (Figure 12b). By contrast, knockdown of endogenous Survivin did not 
alter G2/M phase (Figure 11), SubG1 fraction or caspase 3/7 activity in Surv. wt 
overexpressing cells (Figure 12). Additionally, knockdown of endogenous Survivin in 
combination with 6 Gy irradiation did not further increase caspase 3/7 activity as compared to 
control siRNA treated cells (Figure 12b). 
According to these results, the BIR domain as well as the XIAP, mictrotubules and Hsp90 
binding sites of Survivin are important for both cell cycle regulation and apoptosis inhibition.  
 
3.1.2 Survivin BIR domain and XIAP binding site are essential for three-dimensional 
radiation clonogenic survival 
Previous studies conducted using colorectal carcinoma cells showed a decreased clonogenic 
survival following knockdown of Survivin in combination with ionizing radiation [125, 127]. 
Plating efficiency of non-irradiated 3D cultured cells was significantly diminished after 
Survivin knockdown in EGFP control, Survivin XIAP, BIR, MicTub and Hsp90 
expressing cells, while recombinant overexpression of Surv. wt rescued the 3D plating 
efficiency (Figure 13a). Overexpression of Survivin wt as well as MicTub and Hsp90 
deletion mutants rescued 3D clonogenic radiation survival while deletion of the Survivin BIR 
domain or XIAP binding site resulted in a significant radiosensitization upon knockdown of 
endogenous Survivin (Figure 13b). A summary of radiation response variables is listed in 
Table 5 that can be found in the appendix. 
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a) 
b) 
 
 
Figure 13: 3D clonogenic radiation survival of cells overexpressing Survivin deletion mutants. (a) 3D 
plating efficiency of cells stably overexpressing the indicated Survivin-EGFP fusion constructs after siRNA-
mediated knockdown of endogenous Survivin. (b) 3D clonogenic radiation survival of cells overexpressing 
Survivin-EGFP fusion constructs. Cells transfected with the empty vector pEGFP served as a control. The assay 
commenced by plating single cells from each cell line and irradiating (X-rays) 24 hours later with the indicated 
doses. Colonies greater than 50 cells were counted 7 days after plating and survival curves with survival fractions 
normalized to the plating efficiency were fitted according to the linear quadratic equation to determine survival 
parameters  [Gy
-1
] and  [Gy
-2
]. Mock: Mock-treated cells; co siRNA: Control siRNA-treated cells; Surv. siRNA: 
Cells treated with siRNA targeted against endogenous Survivin; n4; *P<0.05; **P<0.01 
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According to these results, the XIAP binding site of Survivin seems to be indispensable for 
three-dimensional radiation clonogenic survival of SW480 colorectal cancer cells.  
In order to confirm these results and ensure that the observed effect was not due to any 
specific behaviour of the specific SW480 clones used in these experiments, the 3D 
clonogenic survival assays were repeated using a set of alternative SW480 clones stably 
transfected with the pEGFP control vector, recombinant Survivin wild type and Survivin 
XIAP. The radiosensitization effect which was observed in the first place in the case of the 
pEGFP vector control and Survivin XIAP (Figure 13b) was similar with that of the alternative 
pEGFP #2, Surv. XIAP #2 while the alternative Surv. wt #2 once again rescued the 
radiation clonogenic survival following knockdown of the endogenous Survivin (Figure 14). 
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Figure 14: 3D radiation clonogenic survival assays with cells expressing alternative clones of Survivin 
deletion mutants. 3D clonogenic radiation survival of three alternative SW480 clones, expressing the indicated 
Survivin-EGFP fusion constructs. Cells transfected with the empty vector pEGFP served as a control. The colony 
forming assay commenced by plating single cells from each cell line (24 hours after the endogenous Survivin 
attenuation) and irradiating (X-rays) 24 hours later with the indicated doses. Colonies greater than 50 cells were 
counted 7 days after plating. Mock: Mock-treated cells; co siRNA: Control siRNA-treated cells; Surv. siRNA: Cells 
treated with siRNA specific for endogenous Survivin. n4; *P<0.05; **P<0.01   
 
These results confirmed the importance of the XIAP binding site of Survivin for 3D radiation 
clonogenic survival of SW480 colorectal cancer cells.   
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3.1.3 Survivin BIR domain and XIAP binding site are essential for regulation of DNA 
double-strand break repair   
Previous work showed that siRNA-mediated knockdown of Survivin in colorectal cancer as 
well as glioblastoma cell lines resulted in increased levels of residual DNA double-strand 
breaks [98, 99]. Since the molecular basis for such an effect requires further investigation, 
the impact of Survivin deletion mutants on DNA DSB repair was analysed via 2D and 3D 
immunofluorescence staining of H2AX and 53BP1 foci of SW480 cells stably transfected 
with Survivin-EGFP deletion constructs following siRNA-mediated knockdown of endogenous 
Survivin and irradiation with 2 Gy.  
Residual DNA damage in both 2D and 3D cell cultures was significantly increased upon 
knockdown of endogenous Survivin in empty vector EGFP, Survivin XIAP and BIR 
expressing cells, as evaluated by counting H2AX and 53BP1 foci 24 h after irradiation with 2 
Gy (Figure 15). On the other hand, overexpression of Survivin wt, MicTub and Hsp90 
constructs rescued DNA damage repair after knockdown of endogenous Survivin in both 2D 
and 3D IF assays (Figure 15).  
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a) 
b)
 
 
Figure 15: Immunofluorescence staining of H2AX/53BP1 foci in cells overexpressing Survivin deletion 
constructs. (a) Two-dimensional and (b) three-dimensional immunofluorescence staining of H2AX/53BP1 foci in 
SW480 cells overexpressing the indicated Survivin-EGFP fusion constructs. 24 hours following siRNA-mediated 
knockdown of endogenous Survivin, cells stably transfected with Survivn-EGFP fusion constructs were plated and 
24 hours thereafter irradiated with 2Gy (0Gy served as a control). 24 hours following irradiation the cells were 
fixed and stained. Cells were stained for 53BP1 and H2AX while nuclei were counterstained with DAPI (blue). 
Foci from at least 50 cells per condition were counted. Bar: 10µm; n=3; *P<0.05; **P<0.01 
 
These data showed the importance of the XIAP binding site of Survivin with regard to 
regulation of residual DNA DSB repair. 
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To confirm our results, we tested alternative SW480 clones, stably transfected with pEGFP 
empty vector (for control), Survivin wild type and Suvivin XIAP binding site deletion construct 
indicated as clones #2. As a result, cells overexpressing the alternative Surv. XIAP #2 
along with the ones bearing the alternative empty vector pEGFP #2 showed the same 
significant increase of residual DNA DSBs following attenuation of endogenous Survivin and 
irradiation with 2Gy, whereas the Surv. wt #2 fully rescued the DNA repair (Figure 16).  
 
 
Figure 16: 3D Immunofluorescence staining of H2AX/53BP1 foci in cells overexpressing alternative 
clones of Survivin deletion constructs. 24 hours following siRNA-mediated knockdown of endogenous Survivin 
cells stably transfected with the indicated Survivn-EGFP fusion constructs were plated and 24 hours thereafter 
irradiated with 2Gy (0Gy served as a control). 24 hours following irradiation the cells were fixed and stained. Cells 
were stained for H2AX and 53BP1 while nuclei were counterstained with DAPI (blue). Foci from at least 50 cells 
per condition were counted. n=3; *P<0.05; **P<0.01  
 
In accordance with these results, the XIAP binding site of Survivin is confirmed to be indeed 
essential for the regulation of DNA DSBs repair. 
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3.1.4 The XIAP binding site of Survivin is essential for interaction with DNA-PKcs 
It has recently been shown that Survivin participates in DNA repair as a member of the non-
homologous end joining (NHEJ) DNA repair machinery co-operating with factors such as 
DNA-PKcs [98, 99]. Thus, after having observed the importance of the XIAP binding site of 
Survivin in DNA DSB repair (Figures 15-16) the Survivin XIAP mutant was chosen for 
further analysis of the interaction between recombinant Survivin and DNA-PKcs via 
immunoprecipitation assays that were performed using SW480 cells stably overexpressing 
the pEGFP empty vector (for control), Survivin-EGFP wild type and Surv. XIAP mutant 
construct.  
 
 
Figure 17: Immunoprecipitation experiments performed with cells overexpressing wild type Survivin and 
its XIAP deletion mutant. Immunoprecipitation (IP) of DNA-PKcs on the left and IP of GFP on the right 
performed with nuclear lysates of SW480 cells stably stransfected with the pEGFP empty vector serving as a 
control, Survivin wild type and Surv. XIAP deletion mutant after irradiation with 4Gy. Co-immunoprecipitated 
proteins were then detected via western blotting. Non-specific isotype antibody (immunoglobulin G or IgG) served 
as an additional control to the EGFP empty vector IP. Recombinant Survivin was detected using an anti-GFP 
antibody (due to pEGFP fusion) while DNA-PKcs was detected using an anti-DNA-PKcs antibody. Representative 
blot of three independent experiments (n=3). 
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DNA-PKcs was found to precipitate with recombinant Surv. wt (and vice versa) but not with 
the XIAP deletion mutant indicating a possibly direct involvement of the XIAP binding site of 
Survivin during interaction with DNA-PKcs (Figure 17). Such an interaction can explain the 
significantly increased radiation-induced DNA DSBs and the clonogenic radiosensitization 
observed in the case of XIAP mutation as opposed to Survivin wt.    
 
3.2 The impact of Survivin phosphorylation on cellular radiation response 
In order to further analyse the impact of post-translational modifications of Survivin on 
cellular radiation response, several phosphorylation mutants were generated involving Serine 
20 (S20), Threonine 34 (T34) and Threonine 117 (T117) phosphorylation sites of the protein. 
In particular, those three sites were mutated to Alanine (A) to constitute a non-
phosphorylatable form of the protein and Aspartic acid (D) for a phosphomimetic (Figure 18). 
All mutations were confirmed twice, once prior to stable transfections (via sequencing of DNA 
from plasmid mini preparations) and once after the stable transfections of SW480 cells via 
sequencing of isolated genomic DNA from the SW480 clones. 
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Figure 18: Symbolic representation of Survivin phosphorylation mutants. Survivin phosphorylation mutants 
fused with EGFP along with the recombinant wild type of the protein and the EGFP empty vector control that were 
used for stable transfection of SW480 cells.   
 
3.2.1 Phosphorylation of Survivin on T34 is important for 3D radiation clonogenic 
survival 
SW480 cells, stably expressing Survivin wt and its phosphorylation mutants were subjected 
to siRNA-mediated knockdown of endogenous Survivin. Prior to the 3D radiation clonogenic 
survival assays, the expression of the mutants as well as the knockdown of the endogenous 
protein were confirmed via western blotting (Figure 19).  
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Figure 19: Western blot conducted with cells overexpressing Survivin phosphorylation mutants. Western 
blot confirmation of recombinant Survivin expression (Survivin-EGFP fusion constructs stably expressed in 
SW480 cells) along with confirmation of the siRNA-mediated knockdown of endogenous Survivin. Anti-Survivin 
and anti-GFP antibodies were used to detect endogenous and recombinant protein expression while β-actin 
served as a loading control. Co: Control siRNA-treated cells; surv: Cells treated with siRNA targeted against 
endogenous Survivin; representative blot of three independent experiments (n=3).  
 
Plating efficiency of non-irradiated 3D cultured cells was significantly compromised after 
attenuation of endogenous Survivin in EGFP control, Survivin S20A, S20D, T34A, T34D, 
T117A and T117D expressing cells, while recombinant overexpression of Surv. wt rescued 
the 3D plating efficiency (Figure 20a). On the contrary, overexpression of Surv. wt as well as 
S20D, T34D, T117A and T117D phosphorylation mutants rescued 3D clonogenic radiation 
survival while the non-phosphorylatable form of Survivin S20A and especially the T34A 
resulted in a radiosensitization effect even prior to the knockdown of endogenous Survivin, 
thus behaving in a dominant negative manner (Figure 20b). 
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a) 
b) 
 
 
Figure 20: 3D clonogenic radiation survival of cells overexpressing Survivin phosphorylation mutants. (a) 
Plating efficiency of 3D clonogenic radiation survival assay performed with SW480 cells that overexpress 
Survivin-EGFP phosphorylation mutants following siRNA-mediated attenuation of endogenous Survivin. (b) 3D 
radiation clonogenic survival of cells overexpressing the indicated Survivin-EGFP phosphorylation mutants. Cells 
transfected with the empty vector pEGFP served as a control. The colony forming assays commenced by plating 
single cells from each cell line and irradiating (X-rays) 24 hours later with the indicated doses. Colonies greater 
than 50 cells were counted 7 days following plating. n3; *P<0.05; **P<0.01     
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A summary of radiation response variables is listed in Table 6 that can be found in the 
appendix. 
Here it is shown that phosphorylation of Survivin on S20 and T34 is essential for clonogenic 
radiation survival (Figure 20b). Both phosphorylation sites are located within the XIAP 
binding site of Survivin (Figure 18). However, due to the poor viability of the S20A mutation, 
the T34A mutant was chosen for further analysis as well as comparison with the XIAP 
construct. Thus, prior to the direct comparison of those two mutations (XIAP and T34A) the 
behaviour of the T34A mutant in 3D radiation clonogenic survival assays was confirmed 
using alternative SW480 clones stably overexpressing phospho-mutant constructs (Figure 
21) in additional clonogenic survival assays. The alternative clone expressing the T34A 
mutation named T34A #2 revealed comparable radiosensitization as shown for the first clone 
(T34A), while the phosphomimetic Survivin T34D clone #2 (T34D #2) dispayed similar 
radioresistance as the first clone (T34D) (Figure 21).  
 
 
Figure 21: 3D clonogenic radiation survival of cells overexpressing alternative clones of Survivin 
phospho-mutants. 3D clonogenic radiation survival assays conducted with SW480 cells stably expressing the 
non-phosphorylatable form of Survivin T34A and the phosphomimetic T34D mutants along with the respective 
alternative clones (marked with #2) following siRNA-mediated knockdown of the endogenous Survivin. The assay 
commenced by plating single cells from each cell line and irradiating (X-rays) with the indicated doses. Colonies 
greater than 50 cells were counted 7 days after plating. n3; *P<0.05; **P<0.01 
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To compare the impact of Survivin T34 phosporylation with the XIAP binding site with regard 
to radiation survival, SW480 cells stably transfected wtth Surv. wt, Surv. XIAP, Surv. T34A 
and Surv. T34D were subjected to siRNA-mediated knockdown of endogenous Survivin. 
Both the expression of the recombinant Survivin and the knockdown of the endogenous 
protein were confirmed via western blotting (Figure 22).  
 
 
Figure 22: Western blotting performed with cells overexpressing Survivin XIAP deletion mutant and 
Survivin T34A or T34D phospho-mutant. Western blot confirmation of the expression of recombinant Survivin 
along with confirmation of the siRNA-mediated knockdown of endogenous Survivin. Anti-Survivin and anti-GFP 
antibodies were used to detect endogenous and recombinant protein expression while β-actin served as a loading 
control. Co: Control siRNA-treated cells; Surv: Cells treated with siRNA targeted against endogenous Survivin. 
Representative blot of four independent experiments (n=4).  
 
Plating efficiency of non-irradiated 3D cultured cells was significantly diminished after 
Survivin knockdown in EGFP control, Survivin XIAP, T34A, and T34D expressing cells 
while overexpression of Survivin wt rescued the 3D plating efficiency (Figure 23a). However, 
overexpression of Survivin wt as well as T34D phospho-mutants rescued 3D clonogenic 
radiation survival while deletion of Survivin XIAP binding site or mutation of Threonine 34 to 
Alanine resulted in a radiosensitization upon knockdown of endogenous Survivin in the case 
of the XIAP and even prior to the knockdown in the case of T34A mutation (Figure 23b).  
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a) 
 
b) 
 
 
Figure 23: 3D clonogenic radiation survival of cells overexpressing the indicated Survivin mutants. (a) 3D 
plating efficiency of cells stably overexpressing Survivin-EGFP fusion constructs namely Surv. wt, Surv. XIAP, 
Surv. T34A and Surv. T34D along with the empty vector pEGFP for control. (b) 3D clonogenic radiation survival of 
cells overexpressing Survivin-EGFP fusion constructs. The assay commenced by plating single cells from each 
cell line and irradiating (X-rays) 24 hours later with the indicated doses. Colonies greater than 50 cells were 
counted 7 days after plating. n4; *P<0.05; **P<0.01 
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These results indicate the importance of the T34 phosporylation site of Survivin, while it is 
not clear whether XIAP binding or binding of different proteins to the XIAP binding site is 
fostered by T34 phosphorylation. 
 
3.2.2 The XIAP binding site and the T34 phosphorylation site of Survivin are essential 
for regulation of residual DNA DSBs repair 
Following the observation of the impact of Survivin deletion mutant XIAP on DNA DSBs 
repair (Figure 15) and the effect of the T34A mutant on 3D radiation clonogenic survival 
(Figure 23b), the latter was chosen for further investigation regarding DNA damage repair 
along with direct comparison with the XIAP mutant.  
Residual DNA damage (as evaluated by counting H2AX and 53BP1 foci in 
immunofluorescence staining assays) 24 h after irradiation with 2 Gy in 3D cell cultures was 
significantly increased upon knockdown of endogenous Survivin in EGFP and Survivin 
XIAP, while T34A expressing cells showed a similar increase of residual DNA damage even 
prior to attenuation of endogenous Survivin (Figure 24a).  
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a) 
 
b) 
 
Figure 24: 3D immunofluorescence staining of H2AX/53BP1 foci in cells overexpressing Survivin 
deletion and phosphorylation mutants. (a) 3D IF of H2AX/53BP1 foci used as a marker for residual DNA 
DSBs. 24 hours following siRNA-mediated knockdown of endogenous Survivin cells stably transfected with the 
indincated Survivn-EGFP fusion constructs were plated and 24 hours thereafter irradiated with 2Gy (0Gy served 
as a control). 24 hours following irradiation the cells were fixed and stained. Cells were stained for 53BP1 and 
H2AX while nuclei were counterstained with DAPI (blue). Foci from at least 50 cells per condition were then 
counted. (b) 3D immunofluorescence staining of alternative (#2) Survivin T34A and T34D clones for confirmation 
of the previous results. n=3; *P<0.05; **P<0.01 
 
However, overexpression of Survivin wt and T34D constructs rescued the DNA damage 
repair after knockdown of endogenous Survivin (Figure 24a).  
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In order to confirm that these results were not clone-dependent, the 3D immunofluorescence 
staining assays were repeated using alternative SW480 clones expressing Survivin T34A 
and T34D phospho-mutants (Figure 24b). As a result, an alternative SW480 Survivin T34A 
#2 clone showed similar significant increase of residual DNA DSBs following irradiation with 
2Gy, whereas an alternative SW480 clone expressing the phospho-mimetic Survivin T34D 
#2 fully rescued residual DNA DSBs repair (Figure 24b).  
 
3.2.3 Mutation of the Survivin T34 phosphorylation site to its non-phosphorylatable 
form T34A prevents interaction with DNA-PKcs 
The XIAP binding site as well as the T34 phosphorylation site of Survivin were shown to be 
implicated in the repair of residual DNA DSBs (Figure 24a). Thus, the Survivin phospho-
mutant T34A along with its phosphomimetic T34D were further analysed in terms of DNA-
PKcs interaction. In order to investigate such an interaction, SW480 cells stably 
overexpressing those Survivin mutants were subjected to subcellular fractionation following 
irradiation with 4 Gy and their nuclear fractions were used for GFP immunoprecipitation 
assays (due to the Survivin-EGFP fusion) (Figure 25). 
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Figure 25: Immunoprecipitation experiment with cells overexpressing Survivin phospho-mutants. IP of 
GFP performed from nuclear lysates of SW480 cells stably stransfected with the pEGFP empty vector serving as 
a control, Survivin T34A and Survivin T34D after irradiation with 4Gy. Associated proteins were then detected via 
Western blotting. Non-specific isotype antibody (immunoglobulin G or IgG) served as an additional control to the 
EGFP empty vector IP. Recombinant Survivin was detected using an anti-GFP antibody while DNA-PKcs was 
detected using an anti-DNA-PKcs antibody. Representative blot of n=4. 
 
The phosphomimetic form of recombinant Survivin T34D was found to co-immunoprecipitate 
with DNA-PKcs while the non-phosphorylatable construct of Survivin T34A did not show such 
an effect proving Survivin phosphorylation at Threonine 34 important for interaction with 
DNA-PKcs.  The fact that the DNA repair factor DNA-PKcs did not co-immunoprecipitate with 
the Survivin T34A mutant might explain at least in part the significantly increased radiation-
induced residual DNA DSBs shown in the immunofluorescence staining assays of the T34A 
mutant versus the phosphomimetic T34D. Additionally, this effect serves as an explanation 
for the clonogenic radiosensitivity observed in the case of T34A mutant as compared to 
Survivin wt and T34D.   
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3.3 Survivin BIR domain, XIAP, Microtubules and Hsp90 binding sites are essential for 
transmigration capability of colorectal cancer cells   
It was recently reported that knockdown of Survivin and/or XIAP in many colorectal cancer 
cell lines leads to a significantly diminished migration capacity [164] revealing the importance 
of Survivin in colorectal cancer cell motility. In this work, attenuation of endogenous Survivin 
decreased transmigration of EGFP control, and XIAP expressing cells compared to control 
siRNA-treated cells while BIR, MicTub and Hsp90 constructs acted as dominant negative 
mutants already significantly repressing transmigration of control cells (Figure 26).  
 
 
Figure 26: Transmigration assay performed with cells overexpressing Survivin deletion mutants. 
Transmigration assay performed with SW480 cells stably transfected with the indicated Survivin-EGFP fusion 
constructs. The assay commenced by plating cells in inserts containing a 8 µm pore size membrane covered with 
a thin layer of matrigel (a laminin-rich extracellular matrix) under serum-free conditions 24h after siRNA-mediated 
knockdown of endogenous Survivin followed by addition of a chemo-attractant (serum-enriched medium). The 
cells that went through the membrane of the inserts (transmigrated cells) were fixed and nuclei were 
counterstained with DAPI. co siRNA: Control siRNA-treated cells; Surv. siRNA: Cells treated with an siRNA 
targeted against endogenous Survivin. n=2; *P<0.05; **P<0.01 
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Knockdown of endogenous Survivin did not further decrease the transmigration rate of BIR, 
MicTub and Hsp90 stably transfected cells. It is hereby shown that not only the binding 
site of XIAP, but also those of Microtubules and Hsp90 are involved in the transmigration 
process suggesting further mechanisms by which Survivin regulates the motility of cancer 
cells. 
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4. Discussion 
The majority of both solid and liquid human tumours are characterized by a dramatic 
overexpression of Survivin [59, 122, 148]  as it has been reported in studies involving 
malignancies of lung [165], breast [166], colon [167], stomach [168], eosophagus [169], 
pancreas [170], liver [171], uterus [172], ovaries [173], Hodgkin’s disease [174], non-
Hodgkin’s lymphoma [175, 176], leukaemias [177, 178] neuroblastoma [179, 180], 
phaeochromocytoma [181], soft-tissue sarcomas [182], gliomas [183] and melanoma [184]. 
The respective normal tissues, however, did not show an expression of Survivin. The 
molecular background of Survivin’s overexpression in tumours is not a mere effect of mitotic 
indices that reflect a higher number of proliferating cells in cancers [184]. Survivin gene 
expression is potentially deregulated showing amplification of its locus on 17q25 in 
neuroblastoma [179], selective demethylation of its exon 1 in ovarian cancer but not in 
normal ovaries [185] as well as loss of wildtype p53 [59]. Survivin is transcriptionally 
repressed by wild-type p53 possibly via modifications in chromatin structure affecting 
promoter accessibility [145, 146, 186]. In the case of colorectal cancer, up-regulation of 
Survivin is thought to originate from APC mutations and aberrant stabilization of -catenin 
[141].  
In particular, Survivin is involved in colorectal carcinogenesis as it stimulates the transition of 
adenomas with low-grade dysplasia into dysplastic lesions and colonic carcinomas in situ 
[148, 187, 188]. Consequently, its expression in malignant tissue renders a prognostic factor 
due to its diagnostic relevance [148]. Increased Survivin expression was found to be 
associated not only with a higher risk of tumour recurrences, but also lymph node 
metastases as well as shorter survival in cases of non-small cell lung cancer [189], T1 
bladder carcinoma [190], meningiomas [191], rectal adenocarcinoma [192] and locally 
advanced prostate cancer [193] treated with radiotherapy or chemo-radiation.  
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In addition, there is substantial evidence proving Survivin to be a radiation resistance factor 
[123-125] the attenuation of which leads to radiosensitization of tumour cells both in vitro and 
in vivo [112, 148]. Studies conducted (in vitro) using glioblastoma, colorectal carcinoma, 
hepatocellular carcinoma and NSCLC cells showed a decreased clonogenic survival 
following knockdown of Survivin in combination with ionizing radiation as well as reduced 
tumour growth in xenograft transplant models [112, 148].  
Apart from participating in cell division and apoptosis, Survivin is a nodal tumour protein 
involved in a multitude of signaling pathways and transcriptional networks [194]. One striking 
feature of this protein is its pronounced ability to co-operate with a plethora of protein 
partners such as other members of the IAP family (like XIAP) as well as components of the 
DNA DSB repair machinery (such as DNA-PKcs). Thus, a further investigation of its 
relationship with members of the IAP family as well as other protein partners (such as 
Hsp90) and DNA repair proteins [98] is necessary in order to figure out the regulatory role of 
Survivin in terms of tumour cell survival and modulation of treatment response. 
The expression of Survivin is controlled at various levels via intracellular sequestration as 
well as protein stability and transcription [148]. In non-malignant cells its expression is 
transcriptionally regulated in a cell-cycle-dependent manner reaching its peak at mitosis 
involving cell-cycle-dependent/cell-cycle gene homology region (CDE/CHR) elements found 
in its promoter [102]. On the contrary, in tumour cells its expression is controlled regardless 
of mitosis [195] by means of various oncogenic pathways [148]. It has been shown that an 
siRNA-mediated knockdown of Survivin in colorectal cancer cells leads to an increased G2/M 
fraction of the cell cycle distribution 24 hours following the knockdown, blocking the cells in a 
more radiosensitive stage of the cell cycle [127, 163]. In the course of this project, after cell 
cycle analysis experiments colorectal cancer cells stably transfected with Survivin lacking its 
BIR domain, XIAP, Microtubules or Hsp90 binding sites were shown to accumulate in the 
Discussion 80 
 
G2/M phase after knockdown of the endogenous protein revealing an implication of these 
particular binding sites of the protein in cell cycle regulation.  
It has been demonstrated that colorectal cancer cells following treatment with siRNA targeted 
against Survivin respond with increased apoptosis and caspase 3/7 activity supporting the 
fact that Survivin promotes tumour cell survival by inhibiting caspases [59, 127]. With the 
exception of XIAP, none of the IAPs is able to directly bind caspases [21]. It is thus believed 
that Survivin can inhibit apoptosis by interacting with other protein partners, with the Survivin-
XIAP complex being a characteristic example of such an interaction during which the XIAP 
binding site of Survivin associates with discontinuous sites in XIAP BIR1 and BIR3 [22, 31]. 
In this study, it was observed that colorectal cancer cells stably expressing Survivin deletion 
mutants (lacking the BIR domain/the XIAP/Microtubules/Hsp90 binding site) showed an 
incompetence to inhibit apoptosis following an siRNA-mediated knockdown of the 
endogenous protein. Therefore, the BIR domain of the protein as well as the XIAP, 
Microtubules and Hsp90 binding sites that were abolished due to the mutations, are 
apparently involved in apoptosis inhibition. 
The radiation clonogenic survival of colorectal cancer cells has been shown to decrease after 
siRNA-mediated attenuation of Survivin [98, 99, 127, 164]. In the present investigation, 
colorectal cancer cells transfected with recombinant Survivin lacking its BIR domain or its 
XIAP binding site were significantly radiosensitized while transfection of cells with Survivin 
MicTub or Hsp90 deletion mutants fully rescued radiation clonogenic survival following the 
knockdown of the endogenous protein, demonstrating a radioresistance equal to that of cells 
overexpressing wild-type recombinant Survivin. Furthermore, cells expressing the non-
phosphorylatable form of Survivin S20A (Serine 20 Alanine) or T34A (Threonine 34 Alanine), 
both of which are located within the XIAP binding site, revealed a radiosensitizing effect even 
prior to endogenous Survivin attenuation thus behaving like dominant negative mutants. On 
the other hand, cells expressing the phosphomimetic version of Survivin S20D (Serine 20 
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Aspartic acid) or T34D (Threonine 34 Aspartic acid) could rescue clonogenic survival.  
However, cells transfected with Survivin phospho-mutant T117A or T117D, located on the 
Microtubules binding site of the protein, did not show such a radiosensitizing effect. 
Consequently, either the interaction between Survivin and XIAP or the XIAP binding site per 
se and/or the S20 or T34 phosphorylation sites, located in that region are vital for radiation 
clonogenic survival of colorectal cancer cells. These results are in line with previously 
published data according to which a phosphomimetic mutant of Survivin namely T34E 
(Threonine 34 Glutamic acid) showed a higher radioresistance than the corresponding 
kinase-dead mutant T34A in human cervical carcinoma HeLa cells [187]. Additionally, 
according to research conducted in our group, depletion of Survivin and/or XIAP resulted in 
comparable effects regarding 3D clonongenic radiation survival [164]. 
Chakravarti and colleagues were the first to observe that Survivin attenuation decreases 
tumour cell survival upon irradiation via caspase-independent mechanisms such as DNA 
repair deficiency [124]. For instance, following Survivin knockdown via siRNA, ASO (anti-
sense oligonucleotide) or YM155 (a small molecule inhibitor of Survivin expression) in 
colorectal and NSCLC cells, a hampered DNA repair was reported [126-128]. In addition, it 
has recently been shown that siRNA-mediated attenuation of Survivin followed by irradiation, 
resulted in a reduction of Ser2056 autophosphorylation of DNA-PKcs, a decrease of DNA-
PKcs kinase activity and increased radiation-induced residual DNA damage in colorectal 
cancer and glioblastoma cells [98, 99].  In order to further investigate the implication of 
Survivin in DNA repair regulation, immunofluorescence evaluation of DSBs was performed 
with cells overexpressing mutated constructs of this protein. Thus, colorectal cancer cells 
transfected with recombinant Survivin following deletion of its XIAP binding site or BIR 
domain revealed a significantly increased residual DNA damage following ionizing radiation 
as compared to the overexpression of recombinant wild-type Survivin. On the contrary, cells 
transfected with Survivin lacking the Microtubules or Hsp90 binding site did not show such an 
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effect being able to substitute the function of endogenous Survivin in terms of DNA repair. 
Apart from cells expressing Survivin XIAP or BIR, cells expressing the non-
phosphorylatable form T34A also exhibited a significantly increased residual DNA damage 
following ionizing radiation. However, cells expressing the phosphomimetic form T34D 
successfully rescued DNA repair following irradiation. In other words, the XIAP binding site 
and/or the T34 phosphorylation site of Survivin are essential for radiation induced residual 
DNA DSBs repair as opposed to the Microtubules or Hsp90 binding sites of the protein. 
Regarding the T34A mutation, these results are in line with previously published data where 
Survivin T34A-transfected cells showed a greater DNA double-strand breakage post-
irradiation in comet assays [124].  
The present data regarding the radiation clonogenic survival as well as the 
immunofluorescence evaluation of DNA DSBs in cells overexpressing Survivin mutants were 
obtained using 3D cell culture systems. It has been shown that 3D cultures reflect better the 
physiological conditions in vivo in terms of cellular radiation response [196] as cell shape and 
cell-to-cell contact are factors of great importance regarding responsiveness to external 
stress [197]. Principally, 3D microenvironment has been reported to confer tumour cell radio-
resistance due to epigenetic differences in terms of chromatin condensation in 3D-grown as 
compared to monolayer cultures [198].    
According to recent studies Survivin accumulates in the nucleus after irradiation and directly 
interacts with DNA repair proteins (involved in NHEJ) such as DNA-PKcs and Ku70 in order 
to regulate DSB repair [98, 99]. In the present study, it was via immunoprecipitation 
experiments observed that Survivin lacking the XIAP binding site as well as the non-
phosphorylatable form T34A did not precipitate with DNA-PKcs, an effect meanwhile present 
in the case of cells expressing wild-type recombinant Survivin (Figure 27).  
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Figure 27: Symbolic diagram of Survivin wt and Surv. XIAP. Representation of Survivin wild type (on top) 
and Survivin lacking the XIAP binding site (on the bottom). It is suggested that DNA-PKcs interacts with Survivin 
within its XIAP binding site and/or only when Survivin is phosphorylated at Threonine 34 while deletion of the 
XIAP binding site abolishes such an interaction.   
 
Thus, it can be suggested that the XIAP binding site and/or the T34 phosporylation site of the 
protein are of great importance not only for apoptosis inhibition [31] but also for DNA DSB 
repair regulation via interaction with DNA-PKcs. The inability of those EGFP-fused constructs 
(Survivin XIAP and Survivin T34A) to interact with this repair protein may at least in part 
explain both the increased residual DNA damage and the diminished radiation clonogenic 
survival of cells overexpressing those constructs.   
Aside from its well-known functions in cellular survival regulation, apoptosis and cell cycle, 
Survivin has recently been described to promote migration and invasion of different tumour 
cells including human LoVo colorectal cancer, breast adenocarcinoma MDA-MB-231, 
prostate adenocarcinoma PC3, melanoma cells or melanocytes [58, 199, 200]. It has further 
been shown that knockdown of Survivin and/or XIAP in multiple colorectal cancer cell lines 
leads to a significantly diminished migration capacity [164]. Principally, the Survivin-XIAP 
complex protects XIAP stability from ubiquitin-dependent degradation while increases 
BIR-Domain -helixNES  XIAP T34
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DNA-PKcs
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caspase inhibition [31, 114], enhances tumour growth in vivo [114] and participates in NF-B 
activation [58]. NF-B activation leads to a transcriptional up-regulation of Survivin [201] 
resulting in an amplification loop that favours cell survival [202] specifically in tumours where 
elevated NF-B activity is related to aggressive disease and metastasis [58, 203]. In more 
detail, the Survivin-XIAP complex activates NF-B, triggering NF-B-dependent  transcription 
of fibronectin, an extracellular matrix protein [58] that in turn engages 1 integrins at cell 
surface, activating cell motility kinases, Src and focal adhesion kinase (FAK) resulting in 
tumour cell migration, invasion and metastatic dissemination in vivo [58]. Despite the 
importance of the Survivin-XIAP complex, modulating tumour cell motility factors such as 
fibronectin expression and FAK, it is hereby shown that not only the XIAP binding site of 
Survivin but also those of Microtubules and Hsp90 are involved in cell migration, suggesting 
further mechanisms via which Survivin participates in cancer cell motility.  
In brief, these results confirm Survivin to function as a radiation resistance factor modulating 
cellular radiation response via DNA DSB repair, induction of cell cycle arrest, apoptosis as 
well as cell motility (Figure 28). 
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Figure 28: Survivin as a radiation resistance factor. Survivin is here depicted to translocate to the nucleus 
following irradiation and regulate DNA repair via interaction with DNA repair proteins; an interaction possible only 
after Survivin phosphorylation at Threonine 34 located within the XIAP binding site of the protein.   
 
It is hereby and for the first time shown that Survivin XIAP binding and T34 phosphorylation 
sites, but not those of Microtubules and Hsp90, are important for radiation clonogenic 
survival and regulation of DNA damage repair, at least in part by disrupting interaction with 
DNA-PKcs. In particular, it is suggested that the DNA repair protein DNA-PKcs interacts with 
Survivin within the latter’s XIAP binding site (amino acids 15-38) and/or only when Survivin is 
phosphorylated at Threonine 34 (Figure 27). 
In addition, XIAP, Microtubules and Hsp90 binding sites as well as the BIR domain were 
demonstrated to be essential for proper cell cycle regulation, apoptosis inhibition and 
transmigration capacity of colorectal cancer cells.  
To a certain extent, these findings have functionally distinguished some of the roles of 
Survivin BIR domain, XIAP, Microtubules and Hsp90 binding sites regarding radiation 
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clonogenic survival, DNA DSBs repair, cell cycle regulation, apoptosis inhibition and 
transmigration of colorectal cancer cells (Figure 29) (also Table 7 in the appendix).  
 
Figure 29: Synopsis of the different binding sites of Survivin and their role in cellular radiation response. 
Schematic representation of Survivin depicting its BIR domain, XIAP, Hsp90 and Microtubules binding sites each 
followed by a brief list of their functions.    
 
For future reference, the interaction between DNA repair proteins and mutated constructs of 
Survivin can be further investigated via DNA-PKcs kinase activity assays and/or mass 
spectrometry-based quantitative proteomics following stable isotope labeling by amino acids 
in cell culture (SILAC). 
In general, the deletion and phosphorylation mutants of this protein along with the 
established cell lines stably overexpressing them, represent a tool to further explore the way 
this protein functions in terms of radiation response and the way it interacts with protein 
partners such as Smac, Aurora Kinase B, INCENP, XIAP, Hsp90 and members of the DNA 
repair machinery. 
A variety of current preclinical studies employing different strategies targeting Survivin 
function or expression produce substantial evidence that such an approach can inhibit 
tumour growth and induce cancer cell-death improving treatment outcome. Hence, there is a 
number of undergoing clinical trials implementing approaches involving anti-sense 
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oligonucleotides against Survivin (such as Gataparsen) as well as transcriptional inhibitors 
(YM155) and immunotherapeutic schemes; the latter using Survivin directed autologous 
cytotoxic T lymphocytes in recurrent oral and colorectal cancer, myeloma and malignant 
melanoma [158-161]. According to early clinical data, those antagonists revealed a relatively 
modest activity having been used as single agents; however, it is believed that if combined 
with conventional chemotherapeutic drugs, monoclonal antibodies or irradiation, they may 
well be of an enhanced therapeutic advantage [148].  
In summary, the present thesis for the first time showed that overexpression of Survivin T34A 
or Survivin lacking its XIAP binding site results in a significant radiosensitization and 
increased levels of unrepaired DNA damage along with no interaction with DNA-PKcs, 
indicating that these mutations interfere with the ability of colorectal cancer cells to repair 
DNA damage following irradiation.  
To conclude, it is hypothesized that phosphorylation of Survivin on Threonine 34 is essential 
for cellular radiation survival proving intervention against Survivin function a promising 
approach to improve the outcome of standard radio-chemotherapeutic treatments. 
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Appendix 
Table 5: Radiation response variables of 3D grown human SW480 colorectal cancer cells. 
 
 
The fit of the dose-effect curves was calculated by means of the linear-quadratic model (ln SF = −α x D − β x D
2
). 
The radiation dose at 50% survival was calculated by transforming the linear quadratic equation (SF = exp [−α x D 
− β x D
2
]) with α and β values of the individual survival curves. The sensitizer enhancement ratio at 50% survival 
(SER) was calculated by dividing the radiation dose at 50% survival of control siRNA (co si) treated cells by the 
 
 
 
Construct 
 Treatment 
 
 
 
 
n 
 
 
 
Plating efficiency 
± SD [%] 
 
 
 
 
α [Gy
-1
] 
 
 
 
 
β [Gy
-2
] 
Radiation 
dose at 
50% cell 
survival 
[Gy] 
 
 
 
SER  
(vs. co si) 
pEGFP        
 mock 4 16.98  ± 4.23 0.1470 0.0118 3.65 0.92 
 co si  7 15.57  ± 5.79 0.1799 0.0078 3.36 1.00 
 Surv. si  7 8.32  ± 3.45 0.3141 0.0014 2.18 1.54 
Surv. wt        
 mock 4 14.23  ± 3.91 0.1311 0.0049 4.53 0.95 
 co si  4 14.58  ± 2.94 0.1531 0.0020 4.29 1.00 
 Surv. si  4 13.36  ± 2.80 0.1067 0.0099 4.56 0.94 
XIAP        
 mock 4 10.89  ± 3.24 0.1762 0,0045 3.60 1.03 
 co si  4 12.24  ± 4.85 0.1866 0.0000 3.72 1.00 
 Surv. si  4 7.24  ± 2.93 0.2409 0.0045 2.74 1.36 
BIR        
 mock 4 13.29  ± 5.49 0.1994 0.0000 3.48 1.04 
 co si  4 12.85  ± 3.84 0.1912 0.0000 3.62 1.00 
 Surv. si  4 6.59  ± 1.86 0.2836 0.0000 2.44 1.48 
MicTub        
 mock 4 14.02  ± 3.78 0.1716 0.0000 4.04 0.94 
 co si  4 15.03  ± 4,47 0.1767 0.0018 3.78 1.00 
 Surv. si  4 9.61  ± 4.47 0.1130 0.0053 4.97 0.76 
Hsp90        
 mock 4 14.18  ± 3.89 0.1332 0.0063 4.32 1.01 
 co si  4 13.63  ± 3.75 0.1363 0.0052 4.36 1.00 
 Surv. si  4 9.33  ± 3.42 0.1158 0.0093 4.42 0.99 
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radiation dose at 50% survival of mock or Survivin siRNA (Surv. si) treated cells. D, radiation dose [Gy]; n, 
number of independent experiments; SD, standard deviation; SF, surviving fraction; pEGFP, enhanced green 
fluorescent protein expressing control; Surv. wt, Survivin wild type; XIAP, Survivin X-linked inhibitor of apoptosis 
protein binding site; BIR, baculovirus IAP repeat domain; MiCTub, Microtubules binding site; Hsp90, Hsp90 
binding site deletion mutants stably expressed in SW480 cells. 
 
Table 6: Radiation response variables of alternative clones and phospho-mutants of 3D 
grown human SW480 colorectal cancer cells. 
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Construct 
 Treatment 
 
 
 
 
n 
 
 
 
Plating efficiency 
± SD [%] 
 
 
 
 
α [Gy
-1
] 
 
 
 
 
β [Gy
-2
] 
Radiation 
dose at 
50% cell 
survival 
[Gy] 
 
 
 
SER  
(vs. co si) 
pEGFP #2          
 co si  4 11.18  ± 4.15 0.1574 0.0123 3.46 1.00 
 Surv. si  4 4.14  ± 1.31 0.3477 0.0019 1.97 1.76 
Surv. wt #2          
 co si  4 10.43  ± 3.10 0.1482 0.0124 3.59 1.00 
 Surv. si  4 9.68  ± 3.76 0.1748 0.0121 3.24 1.11 
XIAP #2          
 co si  4 8.29  ± 1.57 0.2188 0.0008 3.13 1.00 
 Surv. si  4 3.62  ± 1.96 0.2687 0.0268 2.13 1.47 
S20A           
 co si  3 8.48  ± 3.31 0.1407 0.0371 2.82 1,00 
 Surv. si  3 3.92  ± 1.63 0.3036 0.0000 2.28 1,24 
S20D           
 co si  3 14.90  ± 3.39 0.0733 0.0220 4.19 1.00 
 Surv. si  3 7.24  ± 2.39 0.1151 0.0219 3.58 1.17 
T34A           
 co si  6 11.15  ± 3.47 0.3076 0.0064 2.16 1.00 
 Surv. si  6 8.00  ± 1.59 0.3202 0.0194 1.94 1.11 
T34D           
 co si  6 13.74  ± 5.47 0.1510 0.0155 3.40 1.00 
 Surv. si  6 10.42  ± 3.84 0.2417 0.0054 2.70 1.26 
T34A #2           
 co si  3 5.37  ± 1.20 0.4427 0.0000 1.57 1.00 
 Surv. si  3 6.86  ± 2.05 0.3396 0.0263 1.79 0.87 
T34D #2           
 co si  3 11.40  ± 1.07 0.1885 0.0156 2.95 1.00 
 Surv. si  3 8.97  ± 0.88 0.3153 0.0073 2.10 1.41 
T117A            
 co si  3 0.15  ± 0.02 0.1834 0.0137 3.07 1.00 
 Surv. si  3 0.11  ± 0.03 0.1296 0.0202 3.47 0.89 
T117D            
 co si  3 0.12  ± 0.03 0.2305 0.0087 2.73 1.00 
 Surv. si  3 0.05  ± 0.02 0.2404 0.0098 2.61 1.05 
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The fit of the dose-effect curves was calculated by means of the linear-quadratic model (ln SF = −α x D − β x D
2
). 
The radiation dose at 50% survival was calculated by transforming the linear quadratic equation (SF = exp [−α x D 
− β x D
2
]) with α and β values of the individual survival curves. The sensitizer enhancement ratio at 50% survival 
(SER) was calculated by dividing the radiation dose at 50% survival of control siRNA (co si) treated cells by the 
radiation dose at 50% survival of mock or Survivin siRNA (Surv. si) treated cells. D, radiation dose [Gy]; n, 
number of independent experiments; SD, standard deviation; SF, surviving fraction; pEGFP, enhanced green 
fluorescent protein expressing control; Surv. wt, Survivin wild type; XIAP, Survivin X-linked inhibitor of apoptosis 
protein binding site; S20A, S20D, T34A, T34D, T117A, T117D mutants stably expressed in SW480 cells. 
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Table 7: Synopsis of observed effects of Survivin mutants on cellular radiation response 
 
Survivin mutation Effects on cellular radiation response or transmigration 
Survivin XIAP 
G2/M arrest, increased values of caspase 3/7 activity, 
increased radiosensitivity, increased levels of DNA DSBs, no 
precipitation with DNA-PKcs, decreased levels of 
transmigration 
Survivin BIR 
G2/M arrest, increased values of caspase 3/7 activity, 
increased radiosensitivity, increased levels of DNA DSBs, 
decreased levels of transmigration 
Survivin MicTub 
G2/M arrest, increased values of caspase 3/7 activity, 
decreased levels of transmigration 
Survivin Hsp90 
G2/M arrest, increased values of caspase 3/7 activity, 
decreased levels of transmigration 
Survivin S20A radiosensitivity 
Survivin S20D - 
Survivin T34A 
increased radiosensitivity, increased levels of DNA DSBs, no 
precipitation with DNA-PKcs 
Survivin T34D - 
Survivin T117A - 
Survivin T117D - 
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Abbreviations 
°C degree Celsius 
H2AX gamma H2A histone, member X 
µg microgram 
µl microliter 
µm micrometer 
µM micromolar 
2D two-dimensional 
3D three-dimensional 
53BP1 p53-binding protein 1 
A Alanine 
ACF Aberrant crypt focus 
AIP Aryl hydrocarbon receptor-interacting protein 
APC Adenomatous polyposis coli gene 
ASO Anti-sense oligonucleotide 
ATM Ataxia telangiectasia mutated 
ATR Ataxia telangiectasia rad3-related protein 
BSA Bovine serum albumin 
BIR Baculovirus IAP repeat  
BRCA1 Breast cancer 1 
BRAF proto-oncogene B-Raf 
CARD Caspase-associated recruitment domain 
CDK1 Cyclin-dependent kinase 1 
CIN Chromosomal instability 
CIMP CpG island methylator phenotype 
cIAPs Cellular inhibitor of apoptosis proteins 
CRC Colorectal cancer 
CO2 Carbon dioxide 
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CFA Colony forming assay 
CPC Chromosomal passenger complex 
c-Ha-Ras V-Ha-ras Harvey rat sarcoma viral oncogene 
homologue 
c-Myc V-myc myelocytomatosis viral oncogene 
homologue (avian) 
D Aspartic acid 
DAPI 4',6-diamidino-2-phenylindole 
DIABLO Direct IAP-binding protein with low pI 
DIAP1 Drosophila IAP 1 
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
DNA-PKcs DNA-dependent protein kinase catalytic 
subunit 
DNA DSBs DNA Double-strand breaks 
EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
FACS Fluorescence-activated cell sorting 
FAK Focal adhesion kinase 
FOXO1 Forkhead box O1 
G2 Growth 2 phase (of the cell cycle) 
GTP-binding protein guanosine nucleotide-binding protein 
HBXIP Hepatitis B virus X-interacting protein 
HIF-1 Hypoxia inducing factor 1 alpha 
HR Homologous recombination 
Hsp90 Heat shock protein 90 
IAP Inhibitor of apoptosis protein 
IBM IAP-binding motif 
IgG Immunoglobulin G 
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IP Immunoprecipitation 
IF Immunofluorescence 
INCENP Inner centromere protein 
KRAS V-Ki-ras2 Kirsten rat sarcoma (viral 
oncogene homolog) 
LB medium Luria Bertani medium 
Lys Lysine 
M Mitotic phase of the cell cycle 
MALT Mucosa-associated lymphoid tissue 
MAPK Mitogen-activated protein kinase 
MDC1 Mediator of DNA damage checkpoint protein 
1 
mg milligram 
min minute 
MicTub Microtubules 
MMR Mismatch repair 
MRN Mre11, Rad50 and Nbs1 complex 
mRNA Messenger RNA 
MSI Microsatellite instability 
mTOR Mammalian target of rapamycin 
n Number of experiments 
NES Nuclear export signal 
ng nanogram 
NF-B nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NHEJ Non-homologous end joining 
NSCLC Non-small cell lung cancer 
p53 Tumour suppressor protein 53 
PCR Polymerase Chain Reaction 
PKA Protein kinase A 
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PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
Plk1 Polo-like kinase 1 
PTEN Phosphatase and tensin homolog deleted 
from chromosome ten 
RNA Ribonucleic acid 
rpm Rounds per minute 
RT Room temperature 
RING Really Interesting Gene 
S serine 
SDS Sodium dodecylsulfate 
siRNA Small interfering RNA 
SIRT1 Silent mating type information regulation 2 
homolog 1 
Smac second mitochondria-derived activator of 
caspases 
SMAD2 (or SMAD4) Mothers against decapentaplegic homolog 2 
(or 4) 
Src proto-oncogene c-Src 
STAAT3 Signal transduction and activator of 
transcription 3 
UBA Binding site for polyubiquitinated proteins 
TBS buffer Tris-buffered saline 
TAE buffer Tris-Acetate-EDTA buffer 
TCF4 Transcription factor 4 
TGF- Transforming growth factor beta 
TNF- Tumour necrosis factor alpha 
TRAIL TNF-related apoptosis-inducing ligand 
TRIS  Tris hydroxymethyl aminomethane 
TP53 Tumour protein 53 (gene) 
wt Wild-type 
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Wnt wingless-related integration site 
XAF1 XIAP-associating factor 1 
XIAP X-chromosome linked inhibitor of apoptosis 
protein 
XRCC4 X-ray repair cross-complementing protein 4 
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